



Publications List

Including Posters, Presentations, Abstracts, and Webcasts

September 2018

[Posters](#)

[Publications](#)

[Publications](#)

[2018](#)

[2017](#)

[2014–
2016](#)

[2008–
2013](#)

[2002–
2007](#)

[1998–
2001](#)

[1991–
1997](#)

2018

[Return to Publications](#)

Alemayehu B, Speiser J, Bloudek L, Sarnes E. Costs associated with long-acting insulin analogues in patients with diabetes. *Am J Manag Care*. 2018 Jul;24(8 Spec No.):SP265-SP272.

Neufeld EJ, Sidonio RF Jr, O'Day K, Runken MC, Meyer K, Spears J. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States. *J Med Econ*. 2018 Aug;21(8):762-769.

Humphries TJ, Rule B, Ogonnaya A, Eaddy M, Lunacsek O, Lamerato L, Pocoski J. Cardiovascular comorbidities in a United States patient population with hemophilia A: a comprehensive chart review. *Adv Med Sci*. 2018 Jul;63(2):329-333.

Morrison VA, Bell JA, Hamilton L, Ogonnaya A, Shih HC, Hennenfent K, Eaddy M, Shou Y, Galaznik A. Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA. *Future Oncol*. 2018 Jun 18. [Epub ahead of print]

Clark R, Bozkaya D, Levenberg M, Faulkner S, Smith TW, Gerberd RA. Topical treatment utilization for patients with atopic dermatitis in the United States, and budget impact analysis of crisaborole ointment, 2%. *J Med Econ*. 2018 May;21:1-8.

Corren J, Kavati A, Ortiz B, Vegesna A, Colby JA, Ruiz K, Panettieri RA Jr. Patient-reported outcomes in moderate-to-severe allergic asthmatics treated with omalizumab: a systematic literature review of randomized controlled trials. *Curr Med Res Opin*. 2018 Jan;34(1):65-80.

Coutinho AD, Raju AD, Wang W, Stafkey-Mailey D, Shetty S, Sander SD. Incremental burden of type 2 diabetes in patients experiencing cardiovascular hospitalizations. *Curr Med Res Opin*. 2018 Jun;34(6):1005-1012.

Coutinho AD, Gandhi K, Fuldeore RM, Landsman-Blumberg PB, Gandhi S. Long-term opioid users with chronic noncancer pain: assessment of opioid abuse risk and relationship with healthcare resource use. *J Opioid Manag*. 2018 Mar/Apr;14(2):131-141.

2017

[Return to Publications](#)

Lamerato L, Price K, Szymialis R, Eaddy M, Ogonnaya A, Shih HC, Ahmad H. Comparative evaluation of treatment patterns and healthcare utilization of newly-diagnosed rheumatoid arthritis patients by anti-cyclic citrullinated peptide antibody status. *J Med Econ*. 2018 Mar;21(3):231-240.

Maiese BA, Pham AT, Shah MV, Eaddy MT, Lunacsek OE, Wan GJ. Hospitalization costs for patients undergoing orthopedic surgery treated with intravenous acetaminophen (IV-APAP) plus other IV analgesics or IV opioid monotherapy for postoperative pain. *Adv Ther*. 2017;34(2):421-435.

Cairo MS, Thompson S, Tangirala K, Eaddy M. A clinical and economic comparison of rasburicase and allopurinol in the treatment of patients with clinical or laboratory tumor lysis syndrome. *Clin Lymphoma Myeloma Leuk*. 2017 Mar;17(3):173-178.

Vega C, Becker RV, Mucha L, Lorenz BH, Eaddy MT, Ogbonnaya AO. Impact of adherence to antidepressants on healthcare outcomes and costs among patients with type 2 diabetes and comorbid major depressive disorder. *Curr Med Res Opin*. 2017 Oct;33(10):1879-1889.

Fazeli Farsani S, Brodovicz KG, Soleymanlou N, Marquard J, Wissinger E, Maiese BA. Incidence and prevalence of diabetic ketoacidosis in adults with type 1 diabetes: a systematic literature review. *BMJ Open*. 2017 Aug 1;7(7):e016587.

Corren J, Kavati A, Ortiz B, Colby JA, Ruiz K, Maiese BA, Cadarette SM, Panettieri RA Jr. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: a systematic literature review. *Allergy Asthma Proc*. 2017 Jul 1;38(4):250-263.

Orange JS, Johnson M, Lennert B, Shields K, Eaddy M. Multispecialty rating of evidence-based conditions for intravenous immunoglobulin therapy using a 3-axis prioritization algorithm. *Am Health Drug Benefits*. 2017 May;10(3):134-142.

Marino J, Ruban C, Saunders W, Blanchette CM. Examining the rate of exacerbations amongst COPD Medicare population with type 2 diabetes. *J Health Econ Outcomes Res*. 2017;5(2):183-193.

François C, Biaggioni I, Shibao C, Ogbonnaya A, Shih HC, Farrelly E, Ziemann A, Duhig A. Fall-related healthcare use and costs in neurogenic orthostatic hypotension with Parkinson's disease. *J Med Econ*. 2017 May;20(5):525-532.

Lokhandwala T, Bittoni MA, Dann RA, D'Souza AO, Johnson M, Nagy RJ, Lanman RB, Merritt RE, Carbone DP. Costs of diagnostic assessment for lung cancer: a Medicare claims analysis. *Clin Lung Cancer*. 2017 Jan;18(1):e27-e34.

Weatherall J, Bloudek L, Buchs S. Budget impact of treating commercially insured type 1 and type 2 diabetes patients in the United States with insulin degludec compared to insulin glargine. *Curr Med Res Opin*. 2017 Feb;33(2):231-238.

Cairo MS, Thompson S, Tangirala K, Eaddy MT. A clinical and economic comparison of rasburicase and allopurinol in the treatment of patients with clinical or laboratory tumor lysis syndrome. *Clin Lymphoma Myeloma Leuk*. 2017 Mar;17(3):173-178.

Ziemssen T, Prosser C, Haas JS, Lee A, Braun S, Landsman-Blumberg P, Kempel A, Gleißner E, Patel S, Huang MY. Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment. *BMC Neurology*. 2017 Mar 27;17(1):62.

Watson C, Prosser C, Braun S, Landsman-Blumberg PB, Gleissner E, Naoshy S. Health care resource utilization before and after natalizumab initiation among patients with multiple sclerosis in Germany. *Clinicoecon Outcomes Res* 2017;9:85-97.

2014–2016

[Return to Publications](#)

Patel V, Schwartz GF, Landsman-Blumberg PB, Lunacsek OE, Wong W. Adherence and persistence of bimatoprost in prior latanoprost users. *Am J Pharm Benefits*. 2016;8(6):e101-e107.

Kiss S, Chandwani HS, Cole AL, Patel VD, Lunacsek OE, Dugel PU. Comorbidity and health care visit burden in working-age commercially insured patients with diabetic macular edema. *Clin Ophthalmol*. 2016;10:2443-2453.

Bramley T, Antao V, Lunacsek O, Hennenfent K, Masaquel A. The economic burden of end-of-life care in metastatic breast cancer. *J Med Econ*. 2016 Nov;19(11):1075-1080.

Nichols KK., Bacharach J, Holland E, Kislán T, Shettle L, Lunacsek O, Lennert B, Burk C, Patel V. Impact of dry eye disease on work productivity, and patients satisfaction with over-the-counter dry eye treatments. *Invest Ophthalmol Vis. Sci*. 2016 Jun 1;57(7):2975-2982.

Patel V, Schwartz GF, Landsman-Blumberg PB. Adherence and persistence of bimatoprost in prior latanoprost users. *Am J Pharm Benefits*. 2016;8(6):e101-e107.

Morland K, Carroll C, Brizner D, Meltzer E, Munzel U, Lipworth B. Implication of alternative minimal clinically important difference threshold estimation methods on technology assessment. *Int J Technol Assess Health Care*. 2016 Jan;32(6):371-375.

Campbell C, Eaddy M, Raju A, Carlton R, Boswell K, Mallick R, Wright D. Treatment patterns and outcomes in patients with varicose veins. *Am Health Drug Benefits*. 2016;9(8):455-465.

Lunacsek O, Ravelo A, Coutinho AD, Hazard S, Green MR, Willey J, Eaddy M, Goertz HP. First-line treatment with bevacizumab and platinum doublet combination in non-squamous non-small cell lung cancer: a retrospective cohort study in US oncology community practices. *Drugs Real World Outcomes*. 2016 Sep;3(3):333-343.

Yaldo A, Wen L, Ogbonnaya A, Valderrama A, Kish J, Eaddy M, Kreilick C, Tangirala K, Shields K. Opioid use among metastatic prostate cancer patients with skeletal-related events. *Clin Ther*. 2016 Aug;38(8):1880-1889.

Jagannath S, Roy A, Kish J, Lunacsek O, Globe D, Eaddy M, Kuriakose ET, Willey J, Butler-Bird S, Siegel D. Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices. *Expert Rev Hematol*. 2016 Jul;9(7):707-717.

Boswell K, Sarnes E, Meyer K, Grossman F, Rajagopalan K, Hassan M. Review of outcomes associated with restricted access to atypical antipsychotics. *Am J Manag Care*. 2016;22(6):e208-e214.

O'Day K, Levy WC, Johnson M, Jacobson AF. Cost-effectiveness analysis of iodine-123 meta-iodobenzylguanidine imaging for screening heart failure patients eligible for an implantable cardioverter defibrillator in the USA. *Appl Health Econ Health Policy*. 2016 Jun;14(3):361-373.

Coutinho A, Lokhandwala T, Boggs RL, Landsman-Blumberg P, Priest J, Stempel DA. Prompt initiation of maintenance treatment following a COPD exacerbation: outcomes in a large insured population. *Int J Chron Obstruct Pulmon Dis*. 2016 Jun 8;11:1223-1231.

Bradford Rice J, White A, Lopez A, Galebach P, Schepman P, Popelar B, Philbin M. Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured US population. *J Med Econ*. 2016 Jul;19(7):649-654.

Bui CN, O'Day K, Flanders S, Oestreicher N, Francis P, Posta L, Popelar B, Tang H, Balk M. Budget impact of enzalutamide for chemotherapy-naïve metastatic castration-resistant prostate cancer. *J Manag Care Spec Pharm*. 2016;22(2):163-170.

Choti MA, Thomas M, Wong SL, Eaddy M, Pawlik TM, Hirose K, Weiss MJ, Kish J, Green MR. Surgical resection preferences and perceptions among medical oncologists treating liver metastases from colorectal cancer. *Ann Surg Oncol*. 2016 Feb;23(2):375-381.

Lokhandwala T, Smith N, Sternhufvud C, Sörstadius E, Lee WC, Mukherjee J. A retrospective study of persistence, adherence, and health economic outcomes of fixed-dose combination vs loose-dose combination of oral anti-diabetes drugs. *J Med Econ*. 2016 Mar;19(3):203-212.

Huh WH, Williams E, Huang J, Bramley T, Poulos N. Cost effectiveness of human papillomavirus—16/18 genotyping in cervical cancer screening. *Appl Health Econ Health Policy*. 2015;13:95-107.

Bloudek L, Eaddy MT, Makenbaeva D. Anticipated impact of generic imatinib market entry on the costs of tyrosine kinase inhibitors. *Am Health Drug Benefits*. 2015;8(9):472-480.

Rodby R, Umanath K, Niecestro R, Jackson JH, Sika M, Lewis JB, Dwyer JP. Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs. *Expert Rev Pharmacoecon Outcomes Res*. 2015 Jun;15(3):545-550.

Nag A, Stanford RH, D'Souza AO. Demographic characteristics of asthma subjects associated with stepping down from fluticasone propionate/salmeterol combination therapy. *Am J Pharm Benefits*. 2015;7(3):e73-e80.

Dalal AA, Patel J, D'Souza A, Farrelly E, Nagar S, Shah M. Impact of COPD exacerbation frequency on costs for a managed care population. *J Manag Care Spec Pharm*. 2015 Jul;21(7):575-583.

Huh WK, Williams E, Huang J, Bramley T, Poulos N. Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screening. *Appl Health Econ Health Policy*. 2015 Feb;13(1):95-107.

Leibson CL, Long KH, Ransom JE, Roberts RO, Hass SL, Duhig AM, Smith CY, Emerson JA, Pankratz VS, Petersen RC. Direct medical costs and source of cost differences across the spectrum of cognitive decline: a population-based study. *Alzheimers Dement*. 2015 Aug;11(8):917-932.

O'Donnell TF, Eaddy M, Raju A, Boswell K, Wright D. Assessment of thrombotic adverse events and treatment patterns associated with varicose vein treatment. *J Vasc Surg: Venous Lym Dis*. 2015;3(1):27-34.

Fernandez-Lopez S. US clears approval pathway for biosimilars: considerations for your practice. *AmerisourceBergen Oncologistics Magazine*. Spring 2015;14(1).

Bell K, Parasuraman S, Raju A, Shah M, Graham J, Denno M. Resource utilization and costs associated with using insulin therapy within a newly diagnosed type 2 diabetes mellitus population. *J Manag Care Spec Pharm*. 2015 Mar;21(3):220-228.

Fernandez-Lopez S, Kazzaz D, Bashir M, McLaughlin T. Assessment of pharmacists' views on biosimilar naming conventions. *J Manag Care Spec Pharm*. 2015 Mar;21(3):188-195.

Abdel-Sattar M, Krauth D, Anglemeyer A, Bero L. The relationship between risk of bias criteria, research outcomes, and study sponsorship in a cohort of preclinical thiazolidinedione animal studies: a meta-analysis. *Evid Based Preclin Med*. 2015 Jan;1(1):11-20.

Schroll JB, Abdel-Sattar M, Bero L. The Food and Drug Administration reports provided more data but were more difficult to use than the European Medicines Agency reports. *J Clin Epidemiol*. 2015 Jan;68(1):102-107.

Law A, McCoy M, Lynen R, Curkendall SM, Gatwood J, Juneau PL, Landsman-Blumberg P. Costs of newborn care following complications during pregnancy and delivery. *Matern Child Health J*. 2015 Sep;19(9):2081-2088.

Diette GB, Dalal AA, D'Souza AO, Lunacsek OE, Nagar SP. Treatment patterns of chronic obstructive pulmonary disease in employed adults in the United States. *Int J Chron Obstruct Pulmon Dis*. 2015 Feb 24;10:415-422.

Seal B, Sullivan SD, Ramsey S, Asche CV, Shermock KM, Sarma S, Zagadailov E, Farrelly E, Eaddy M. Evaluating treatments and corresponding costs of prostate cancer patients treated within an inpatient or hospital-based outpatient setting. *Future Oncol*. 2015;11(3):439-447.

Mytelka D, Li L, Stafkey-Mailey D, Liepa A, Hess L, Farrelly E, Eaddy M. Treatment patterns and outcomes among patients with high-intermediate/high-risk diffuse large B-cell lymphoma in the USA [published online ahead of print December 31, 2014]. *Hematology*. 2014.

Carlton R, Lunacsek O, Regan T, Carroll CA. Healthcare costs among patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder, or narcolepsy. *Am Health Drug Benefits*. 2014;7(6):334-340.

Minkowitz HS, Scranton R, Gruschkus SK, Nipper-Johnson K, Menditto L, Dandappanavar A. Development and validation of a risk score to identify patients at high risk for opioid-related adverse drug events. *J Manag Care Pharm*. 2014;20(8):948-958.

Seal B, Sullivan S, Ramsey S, Ache C, Shermock K, Sarma S, Zagadailov E, Farrelly E, Eaddy M. Comparing hospital-based resource utilization and costs for prostate cancer patients with and without bone metastases. *Appl Health Econ Health Policy*. 2014 Oct;12(5):547-557.

Polonsky WH, Thompson S, Wei W, Riddle MC, Chaudhari S, Jackson J, Bruno AS. Greater fear of hypoglycaemia with premixed insulin than with basal-bolus insulin glargine and glulisine: patient-reported outcomes from a 60-week randomised study. *Diabetes Obes Metab*. 2014 Nov;16(11):1121-1127.

Lalla D, Carlton R, Santos E, Bramley T, D'Souza A. Willingness to pay to avoid metastatic breast cancer treatment side effects: results from a conjoint analysis. *SpringerPlus*. 2014;3:350 (July 10, 2014).

Ryan CJ, Buettner A, Britton SL, Lankford M, Neely DB, Green MR. Prospective evaluation of prescribing preferences (PPrefs) of U.S.-based oncologists in the postdocetaxel mCRPC patient (Pt). *J Clin Oncol*. 32, 2014 (suppl; abstr e16011) [published online].

Senbetta M, Dandappanavar A, McKenzie RS, Ellis L, O'Day K. Ibrutinib therapy for patients with relapsed or refractory mantle cell lymphoma: a budget impact analysis from a U.S. payer perspective. *J Clin Oncol*. 32, 2014 (suppl; abstr e19553) [published online].

Faria C, Jackson J, Lunacsek O, Hennenfent KL. Time to progression and time to treatment failure in patients with triple-negative metastatic breast cancer receiving eribulin mesylate in a community oncology setting. *J Clin Oncol*. 32, 2014 (suppl; abstr e12039) [published online].

Seal BS, Xia F, Germino F, Rietschel P, Asche CV, D'Souza AO, Morland K, Eaddy M. An evaluation of national treatment trends in pancreatic cancer. *J Clin Oncol*. 32, 2014 (suppl; abstr e15211) [published online].

Stafkey-Mailey D, Seal BS, Xia F, Rietschel P, Germino R, Asche CV, Zagadailov E, Eaddy M. An evaluation of national treatment trends and survival in GIST. *J Clin Oncol*. 32, 2014 (suppl; abstr e21510) [published online].

Saleh MN, Haislip S, Sharpe J, Hess T, Gilmore J, Jackson J, Sail KR, Ericson SG, Chen L. Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community setting. *Curr Med Res Opin*. 2014 Apr;30(4):529-536.

Kruep EJ, Phillips E, Hogue S, Eaddy M. Early symptom improvement and discontinuation of 5- α -reductase inhibitor (5ARI) therapy in patients with benign prostatic hyperplasia (BPH). *Ann Pharmacother*. 2014 Mar;48(3):343-348.

2008–2013

[Return to Publications](#)

Roy S, Bramley TJ, Hinoul P, Migliaccio-Walle K, Li H. Economic considerations for mid-urethral sling procedures among patients with stress urinary incontinence. *J Long Term Eff Med Implants*. 2013;23(1):1-8.

Esposito D, Migliaccio-Walle K. *Reliability and Validity of Data Sources for Outcomes Research & Disease and Health Management Programs*. Lawrenceville, NJ: ISPOR, 2013.

Ollendorf DA, Migliaccio-Walle K, Colby JA, Pearson SD. Management options for children with attention deficit hyperactivity disorder: a regional perspective on value. *J Comp Eff Res*. 2013 May;2(3):261-271.

Simpson KN, Pei PP, Möller J, Baran RW, Dietz B, Woodward W, Migliaccio-Walle K, Caro JJ. Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States. *Pharmacoeconomics*. 2013 May;31(5):427-444.

Jain G, Roy A, Harikrishnan V, Yu S, Dabbous O, Lawrence C. Patient-reported depression severity measured by the PHQ-9 and impact on work productivity: results from a survey of full-time employees in the United States. *J Occup Environ Med*. 2013 Mar;55(3):252-258.

Lawrence C, Roy A, Harikrishnan V, Yu S, Dabbous O. Association between severity of depression and self-perceived cognitive difficulties among full-time employees. *Prim Care Companion CNS Disord*. 2013;15(3): PCC.12m01469. doi: 10.4088/PCC.12m01469. Published online May 30, 2013.

Chancellor MB, Migliaccio-Walle K, Bramley TJ, Chaudhari SL, Corbell C, Globe D. Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder. *Clin Ther*. 2013 Nov;35(11):1744-1751.

Shah M, Winfree K, Peterson K, Gruschkus S, Eaddy M, Green M. Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting. *Lung Cancer*. 2013 Oct;82(1):121-127.

O'Day K, Rajagopalan K, Meyer K, Pikalov A, Loebel A. Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US. *Clinicoecon Outcomes Res*. 2013 Sep;5:459-470.

Zagadailov E, Fine M, Shields A. Patient-reported outcomes are changing the landscape in oncology care: challenges and opportunities for payers. *Am Health Drug Ben*. 2013 Jul;6(5):264-274.

Rajagopalan K, O'Day K, Meyer K, Pikalov A, Loebel A. Annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-release. *J Med Econ*. 2013 Aug;16(8):987-996.

Rajagopalan K, Hassan M, O'Day K, Meyer K, Grossman F. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data. *J Med Econ*. 2013 Jul;16(7):951-961.

Seal B, Asche C, Puto K, Allen P. Efficacy, patient-reported outcomes (PROs), and tolerability of the changing therapeutic landscape in patients with metastatic prostate cancer (MPC): a systematic literature review. *Value Health*. 2013 Jul-Aug;16(5):872-890.

Lennert B, Farrelly E, Sacco P, Pira G, Frost M. Resource utilization in children with tuberous sclerosis complex and associated seizures: a retrospective chart review study. *J Child Neuro*. 2013 Apr;28(4):461-469.

Denno M, Brown L, Jackson J. Impact of the NCCN biomarkers compendium on managed care pharmacy. *JMCP*. 2013 Jan/Feb;19(1):68-69.

Stanford R, Shah M, D'Souza A, Schatz M. Predicting asthma outcomes in patients within commercially insured and Medicaid populations. *Am J Manag Care*. 2013 Jan;19(1):60-67.

Kruep E, Goodwin B, Chaudhari S. Evaluation of recent trends in treatment patterns among men with benign prostatic hyperplasia. *Am J Mens Health*. 2013 May;7(3):214-219.

Parker K, Zagadailov E, Bruno A, Wiland A. Transplant coordinators' perceived impact of availability of multiple generic immunosuppression therapies on patients, workload, and posttransplant maintenance therapy. *J Transplant*. 2013:1-7.

Stanford R, Shah M, D'Souza A. Fluticasone propionate-salmeterol versus inhaled corticosteroids plus montelukast: outcomes study in pediatric patients with asthma. *J Asthma Allergy*. 2013;6:1-10.

Dupclay L, Eaddy M, Jackson J, Raju A, Shim A. Real-world impact of reminder packaging on antihypertensive treatment adherence and persistence. *Patient Prefer Adherence*. 2012;6:499-507.

Feinberg B, Gilmore A, Haislip S, Gilmore J, Jain G, Whyte JL. Hemoglobin trends and anemia treatment due to concomitant chemotherapy in community oncology clinics. *J Oncol*. 2012 Jan;8(1):18-23.

Eaddy M, Kruep E, Lunacsek O, Goodwin B. Establishing the clinical and economic benefits of adherence to 5-alpha reductase inhibitors in benign prostatic hyperplasia: an assessment of Medicare and Medicaid patients. *Expert Opin Pharmacother*. 2012;13(18):2593-2600.

Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. *Am Health Drug Ben*. 2012 Sep/Oct;5(6):347-357.

Stanford R, Shah M, D'Souza A, Dhamane A, Schatz M. Short-acting β -agonist use and its ability to predict future asthma-related outcomes. *Ann Allergy Asthma Immunol*. 2012 Dec;109(6):403-407.

Dalal A, Shah M, D'Souza A, Lunacsek O, Nagar S, Crater G. Observational study of the outcomes and costs of initiating maintenance therapies in patients with moderate exacerbations of COPD. *Respir Res*. 2012;13:41.

Boswell KA, Wang X, Shah MV, Apro MS. Disease burden and treatment outcomes in second-line therapy of patients with estrogen receptor-positive (ER+) advanced breast cancer: a review of the literature. *Breast*. 2012;21:701-706.

Lee CT, Barocas D, Globe DR, Oefelein MG, Colayco DC, Bruno A, O'Day K, Bramley T. Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases. *J Urol*. 2012 Dec;188(6):2114-2119.

Eaddy M, Seal B, Tangirala K, Davies E, O'Day K. Economic implications of rasburicase treatment in adult patients with tumour lysis syndrome. *Appl Health Econ Health Policy*. 2012;10(6):431-440.

Howel P, Burich M. Biosimilars: an uncertain path to promise. As the costs of drugs rise, will biosimilars fulfill their promise of affordability? *Pharmpro*. 2012 Oct:36-37.

Dalal A, Shah M, D'Souza A, Crater G. Rehospitalization risks and outcomes in COPD patients receiving maintenance pharmacotherapy. *Respir Med*. 2012;106(6):829-837.

Dalal A, Shah M, D'Souza A, Dhamane A, Crater G. Outcomes associated with timing of maintenance treatment for COPD exacerbation. *Am J Manag Care*. 2012;18(9):e338-e345.

Patel A, Lennert B, Macomson B, Nelson W, Owens G, Mody S, Schein J. Anticoagulant use for prevention of stroke in a commercial population with atrial fibrillation. *Am Health Drug Benefits*. 2012;5(5):291-298. <http://www.ahdbonline.com/feature/anticoagulant-use-prevention-stroke-commercial-population-atrial-fibrillation>.

Gruschkus S, Poston S, Eaddy M, Chaudhari S. Adherence to 5-alpha reductase inhibitor therapy for benign prostatic hyperplasia. *P T*. 2012 Aug;37:8:464-470.

Moore Simas T, Warings M, Liao X, Garrison A, Sullivan G, Howard A, Hardy J. Prepregnancy weight, gestational weight gain, and risk of growth affected neonates. *J Womens Health*. 2012;21(4):410-417.

LaBounty TM, Shah M, Raman SV, Lin FY, Berman DS, Min JK. Within-hospital and 30-day outcomes in 107,994 patients undergoing invasive coronary angiography with different low-osmolar iodinated contrast media. *Am J Cardiol*. 2012 Jun 1;109(11):1594-1599.

Boswell KA, Cook CL, Burch SP, Eaddy MT, Cantrell RC. Associating medication adherence with improved outcomes: a systematic literature review. *Am J Pharm Benefits*. 2012;4(4):e97-e108.

Stanford R, Manan S, Chaudhari S. Clinical and economic outcomes associated with low-dose fluticasone propionate versus montelukast in children with asthma aged 4 to 11 years. *Open Respir Med J*. 2012;6:37-43.

Brown L. Gain a solid understanding of compendia and its impact on patient access. *Formulary*. 2012 Jul;47:2-6.

Green M, Brown L. The promising outlook with immunoconjugate therapy. *Oncol Bus Rev*. 2012 Jul;22-25.

Hastings A, Byers C, Bercu B. Chapter 11: Navigating the IRB for Investigators. In: Melnyk BM, Morrison-Beedy D, eds. *Intervention Research Designing Conducting, Analyzing, and Funding*. New York, NY: Springer Publishing Company, LLC; 2012:169-191. <http://www.springerpub.com/product/9780826109576>.

Howell P. How much cheaper will biosimilars be? *FiercePharma*. 2012 Mar 2. <http://www.fiercepharma.com/story/how-much-cheaper-will-biosimilars-be/2012-03-02>.

Ye X, Rupnow M, Hammond J, Shah M, Farrelly E. Readmission rates and hospital costs associated with fibrin sealant use among patients undergoing orthopedic surgery. *J Orthopaedics*. 2012;9(1):e11. <http://www.jortho.org/2012/9/1/e11/index%2011.html>.

Tanner N, Gomez M, Rainwater C, Nietert P, Simon G, Green M, Silvestri G. Physician preferences for management of patients with stage IIIA NSCLC: impact of bulk of nodal disease on therapy selection. *J Thorac Oncol*. 2012 Feb;7(2):365-369.

Miller R, Happe L, Meyer K, Spear R. Approaches to the management of agents used for the treatment of multiple sclerosis: consensus statements from a panel of U.S. managed care pharmacists and physicians. *J Manag Care Pharm*. 2012 Jan/Feb;18(1):54-62.

Chatterjee A, Shah M, D'Souza AO, Bechtel B, Crater G, Dalal A. Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease. *Respir Res*. 2012 Feb 17;13(1):15.

Dalal A, Shah M, D'Souza AO, Chaudhari S, Crater G. Clinical and economic outcomes for patients initiating fluticasone propionate/salmeterol combination therapy (250/50 mcg) versus anticholinergics in a comorbid COPD/depression population. *Int J Chron Obstruct Pulmon Dis*. 2012 Jan 18;7:11-19.

Eaddy M, Cook C, O'Day K, Burch S, Cantrell R. How patient cost-sharing trends affect adherence and outcomes, a literature review. *P T*. 2012 Jan;37(1):45-55.

Epstein J, Xiong Y, Luo M, Li-McLeod J. Benefits associated with a broad selection of dosage strengths for recombinant factor VIII products. *Haemophilia*. 2012 Mar;18(2):182-186.

Feinberg BA, Gilmore A, Lunacsek O, Haislip S, Yu E, Yim Y, Gilmore JW. Patient (Pt)-reported symptoms of chemotherapy (chemo) and VEGFR/EGFR antibody therapies for the treatment of metastatic colorectal cancer (MCR) in a US community-based oncology practice network. *J Clin Oncol*. 2011;29(suppl 4; abstr 575).

Bordoni R, Feinberg B, Gilmore J, Haislip S, Jackson J, Farrelly E, Kim E, Buchner D. Hematologic outcomes of myelodysplastic syndromes treatment with hypomethylating agents in community practice. *Clin Lymphoma Myeloma Leuk*. 2011 Aug;11(4):350-354.

Ready NE, Dudek AZ, Pang HH, Hodgson LD, Graziano SL, Green MR, Vokes EE. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. *J Clin Oncol*. 2011 Nov 20;29(33):4436-4441.

Yeung W, Burns III H, Loiacono D. Are ACOs the answer to high-value healthcare? *Am Health Drug Benefits*. 2011;4(7):441-450.

Lamerato L, Kruep E, Hogue S, Chaudhari S, Eaddy M. Outcomes with early versus delayed 5ARIs for benign prostatic hyperplasia. *Am J Pharm Benefits*. 2011 Nov/Dec;3(6):e127-e134.

Shenolikar R, Bruno A, Eaddy M, Cantrell C. Sensitivity of medication use to formulary controls in Medicare beneficiaries: a review of the literature. *Am Health Drug Benefits*. 2011;4(7):465-474.

Agashivala N, Dastani H, Carlton R, Sarnes E. Cost-effectiveness of fingolimod in treating patients with relapsing-remitting multiple sclerosis. *Am J Pharm Benefits*. 2011;3(6):320-328.

Allen P, Fuentes R, Hoopes M, Susla G. Evaluation of drug adverse event intake and reporting in a medical information service. *Drug Info J*. 2011;45(6):767-773.

May D, Shields S. Healthcare reform brings opportunities and risks: learn what the Affordable Care Act means to you and your practice. *Optometric Management*. October 2011.
<http://www.optometric.com/article.aspx?article=106299>.

Bonnet P, Gringeri A, Gomperts E, Leissing CA, d'Oiron R, Teitel J, Young G, Franklin M, Ewenstein B, Berntorp E. Modeling costs and outcomes associated with a treatment algorithm for problem bleeding episodes in patients with severe hemophilia A and high-titer inhibitors. *Am Health Drug Benefits*. 2011;4(4):219-229.

Sarnes E, Crofford L, Watson M, Dennis G, Kan H, Bass D. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. *Clin Ther*. 2011 Oct;33(10):1413-1432.

Madison T. Regional variations. *Int Clin Trials*. 2011 Nov:88-94.

Jackson J, Kohn-Parrott K, Parker C, Levins N, Dyer S, Hedalen E, Frank E, Bramer S, Brandt D, Doyle J. Blood pressure success zone: you auto know—a worksite-based program to improve blood pressure control among auto workers. *Popul Health Manag*. 2011 Oct;14(5):257-263.

Waters H, Vanderpoel J, Nejadnik B, Lunacsek O, Lennert B, Goff J, Augustyn D, McKenzie S. Resource utilization before and during infliximab therapy in patients with inflammatory bowel disease. *J Med Econ*. 2011;15(1):45-52.

Kruep EJ, Hogue S, Eaddy M, Chandra M. Clinical and economic impact of early versus delayed 5-alpha reductase inhibitor therapy in men taking alpha blockers for symptomatic benign prostatic hyperplasia. *P T*. 2011 Aug;36(8):493-507.

Dalal A, Shah M, Lunacsek O, Hanania N. Clinical and economic burden of depression/anxiety in chronic obstructive pulmonary disease patients within a managed care population. *COPD*. 2011;8:293-299.

Brown L, Pih J. Payers and providers agree: realistic expectations and cost-effective analyses are key. *Oncol Bus Rev*. 2011 Jul:8-14. <http://www.oncbiz.com/journal-obrgreen-201107.php>.

O'Day K, Meyer K, Miller R, Agarwal S, Franklin M. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis. *J Med Econ*. 2011;14(5):617-627.

Bruno A, ed. The 2011 Genentech Oncology Cost Trend Report: Oncology Utilization and Cost Trends in Three Leading Cancers. South San Francisco, CA: Genentech; 2011.

Stokes M, Ye X, Shah M, Mercaldi K, Reynolds M, Rupnow M, Hammond J. Impact of bleeding-related complications and/or blood product transfusions on hospital costs in inpatient surgical patients. *BMC Health Serv Res*. 2011;11:135.

Schwartzberg L, Jackson J, Jain G, Balu S, Buchner D. Impact of 5-HT₃ RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting. *Expert Rev Pharmacoecon Outcomes Res*. 2011 Aug;11(4):481-488.

Naslund M, Eaddy M, Hogue SL, Kruep EJ, Shah M. The economic impact of delaying 5-alpha reductase inhibitor therapy in men receiving treatment for symptomatic benign prostatic hyperplasia. *Am Health Drug Ben*. 2011 May/Jun;4(3):155-162.

Mauceri E, Bienkowski C, Hanson K, Doyle JJ, Jackson J, Bramer S. A health outcome assessment of the cardio metabolic mission health program at Novartis. *J Occup Environ Med*. 2011 Jun;53(6):647-652.

Pettaway C, Lamerato L, Eaddy M, Edwards J, Hogue S, Crane M. Benign prostatic hyperplasia: racial differences in treatment patterns and prostate cancer prevalence. *BJU Int*. 2011 Oct;108(8):1302-1308.

Feinberg B, Gilmore J, Haislip S, Jackson J, Jain G, Balu S, Buchner D. Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy. *SpringerLink – Supportive Care in Cancer, Online First* (online access only). 2011 Mar 29;19(3),1-9.

Dalal A, Shah M, D'Souza AO, Rane P. Costs of COPD exacerbations in the emergency department and inpatient setting. *Respir Med*. 2011 Mar;105(3):454-460.

Dalal AD, Shah M, D'Souza A, Mapel DW. COPD-related healthcare utilization and costs after discharge from a hospitalization or emergency department visit on a regimen of fluticasone propionate-salmeterol combination versus other maintenance therapies. *Am J Manag Care*. 2011 Mar;17(3):e55-e65.

Schwartzberg L, Szabo S, Gilmore J, Haislip S, Jackson J, Gagan J, Balu S, Buchner D. Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately or highly emetogenic chemotherapy (LEC/MEC/HEC). *Curr Med Res Opin*. 2011;27(4):837-845.

- Fonseca V, Sharma PP, Shah M, Deedwania P. Original article: risk of new-onset diabetes mellitus associated with beta-blocker treatment for hypertension. *Curr Med Res Opin.* 2011;27(4):799-807.
- Langley PC, Patkar AD, Boswell KA, Benson CJ, Schein JR. Adverse event profile of tramadol in recent clinical studies of chronic osteoarthritis pain. *Curr Med Res Opin.* 2010;26:239-251.
- Eaddy M, Seal B, Tangirala M, Davies E, O'Day K. Economic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patients. *Am J Health-Syst Pharm.* 2010;67:2110-2114.
- Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis: a literature review from a global health systems perspective. *P T.* 2010;35(12):680-689.
- Boswell K, Kwong WJ, Kavanagh S. Burden of opioid-associated gastrointestinal side effects from clinical and economic perspectives: a systematic literature review. *J Opioid Manag.* 2010;6(4):269-289.
- D'Souza A, Meissner BL, Tang B, McKenzie RS, Piech CT. Effectiveness of anti-tumor necrosis factor agents in the treatment of rheumatoid arthritis: observational study. *Am Health Drug Benefits.* 2010;3(4):266-273.
- D'Souza AO, Rahnema R, Regan TS, Common B, Burch S. H-E-B's value-based health management program: impact on asthma medication adherence and healthcare cost. *Am Health Drug Benefits.* 2010;3(6):394-402.
- Park J, Jackson J, Skinner E, Ranghell K, Saiers J. Impact of an adherence intervention program of medication adherence barriers, asthma control, and productivity/daily activities in patients with asthma. *J Asthma.* 2010 Dec;47(10):1072-1077
- Johnson PE, Dahlman G, Eng K, Garg R, Gottlieb S, Hoffman JM, Howell P, Jahanzeb M, Johnson S, Mackler E, Rubino M, Sarokhan B, Stewart M, Tyler T, Vose JM, Weinstein S, Li EC, DeMartino J. NCCN oncology risk evaluation and mitigation strategies white paper: recommendations for stakeholders. *JNCCN.* 2010;8(Suppl 7):S7-S27.
- Butts CA, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D, Johnson DH, Kesler KA, Green M, Vincent M, Cormier Y, Goss G, Findlay B, Johnston M, Tsao MS, Shepherd FA. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. *J Clin Oncol.* 2010 Jan 1;28(1):29-34.
- Bogart JA, Hodgson L, Seagren SL, Blackstock AW, Wang X, Lenox R, Turrisi AT 3rd, Reilly J, Gajra A, Vokes EE, Green MR. Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904. *J Clin Oncol.* 2010 Jan 10;28(2):202-206.
- Graziano SL, Gu L, Wang X, Tatum AH, Vollmer RT, Strauss GM, Kratzke R, Dudek AZ, Vokes EE, Green MR. Prognostic significance of mucin and P53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633. *J Thorac Oncol.* 2010;5:810-817.
- Ready N, Jänne PA, Bogart J, Dipetrillo T, Garst J, Graziano S, Gu L, Wang X, Green MR, Vokes EE. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. *J Thorac Oncol.* 2010 Sep;5(9):1382-1390.
- Dalal A, Shah M, D'Souza AO, Rane P. Costs of inpatient and emergency department care for chronic obstructive pulmonary disease in an elderly Medicare population. *J Med Econ.* 2010;13(4):591-598.
- Foster T, Edwards D, Lumpkin M, Hubbard W, Cayetano M, Fernandez-Lopez S. Models and mechanisms for assisting the underinsured. *Oncol Bus Rev.* 2010 May;3:1-5. www.oncbiz.com.

Akhress F, Skinner N, Boswell K, Travis LB. Evolving trends in insulin delivery: in pursuit of improvements in diabetes management. *Am Health Drug Ben*. 2010 Mar/Apr;3(2):117-122.

Neutel JM, Eaddy M, Lunacsek OE, Roberts C, Chen L, Kean AJ, Jackson JH. Predicted coronary heart disease risk reduction and dual blood pressure/cholesterol goal attainment in patients with hypertension treated in real-world clinical practice. *J Clin Hypertension*. Published online: 2010 April.

Soper AM, Reeder CE, Brown LM, Stojanovska A, Lennert BJ. The national oncology working group (now) initiative: payer and provider collaborations in oncology benefits management. *Am J Manag Care*. 2010;16(4):e94-e97.

Bramley TJ. Evidence-based medicine and comparative effectiveness research: toward appropriate utilization of biopharmaceuticals in multiple sclerosis. *Am Health Drug Benefits*. 2010 Jan/Feb;3(1)4:S54-S58.

Carlton RI, Bramley TJ, Nightengale B, Conner TM, Zacker C. Review of outcomes associated with formulary restrictions: focus on step therapy. *Am J Pharm Benefits*. 2010;2(1):50-58.

Crawford ED, Black L, Eaddy M, Kruep EJ. A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer. *Prostate Cancer Prostatic Dis*. 2010 Jun;13(2):162-167.

Min JK, Gilmore A, O'Day K, Budoff MJ. The cost-effectiveness of coronary computed tomography Angiography versus Myocardial perfusion SPECT imaging for the evaluation of patients with chest pain and no known coronary artery disease. *Radiology*. 2010 Mar;254(3):801-808.

Smith BJ, St Louis EK, Stern JM, Green C, Bramley T. Concerns with AED conversion: comparison of patient and physician perspectives. *Curr Neuropharmacol*. 2009 Jun;7(2):120-124.

Garnett WR, St Louis EK, Henry TR, Bramley T. Transitional polytherapy: tricks of the trade for monotherapy to monotherapy AED conversions. *Curr Neuropharmacol*. 2009 Jun;7(2):83-95.

St Louis EK, Rosenfeld WE, Bramley T. Antiepileptic drug monotherapy: the initial approach in epilepsy management. *Curr Neuropharmacol*. 2009 Jun;7(2):77-82.

Fernandez-Lopez S, Lennert B. Quality improvement initiatives: the missed opportunity for health plans. *Am Health Drugs Benefits*. 2009 Nov/Dec;2(7):297-304.

Saverno K, Seal B, Goodman MJ, Meyer K. Economic evaluation of quality-of-life improvement with second-generation antihistamines and montelukast in patients with allergic rhinitis. *Am Health Drug Benefits*. 2009 Nov/Dec;2(7):309-316.

Naslund M, Eaddy MT, Hogue SL, Kruep EJ, Shah MB. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery. *Curr Med Res Opin*. 2009;25(11):2663-2669.

Lennert B. Care management for TIA and stroke patients: riding the quality improvement wave. *Am Health Drugs Benefits*. 2009 Sep/Oct;2(6)8Suppl:S24-S27.

Green MR, West H, Socinski MA, Willey J, Daniels L, Lemke K, Rafferty G, Iovino L. Impact of the ASCO 2007 presentation of HOG Lun 01-24/USO-023 on the prescribing plans of American medical oncologists for patients with stage IIIB non-small cell lung cancer. *J Thorac Oncol*. 2009 Aug;4(8):983-987.

St. Louis EK, Rosenfeld WE, Bramley T. Antiepileptic drug monotherapies: the initial approach in epilepsy drug monotherapy. *Curr Neuropharmacol*. 2009;7:77-82.

- Garnett WR, St. Louis EK, Henry T, Bramley T. Transitional polytherapy: trick of the trade for monotherapy to monotherapy conversions. *Curr Neuropharmacol*. 2009;7:83-95.
- Bonnet PO, Yoon BS, Wong WY, Boswell K, Ewenstein BM. Cost minimization analysis to compare activated prothrombin complex concentrate (APCC) and recombinant factor VIIa for hemophilia patients with inhibitors undergoing major orthopedic surgeries. *Haemophilia*. 2009 Sep;15(5):1083-1089.
- Garris C, Shah M, D'Souza A, Stanford R. Comparison of corticosteroid nasal sprays in relation to concomitant use and cost of other prescription medications to treat allergic rhinitis symptoms, retrospective cohort analysis of pharmacy claims data. *Clin Drug Invest*. 2009;29(8):515-526.
- Feinberg B, Gilmore J, Gondesens T, Jackson J, Saleh M. Impact of NCD guidelines on Medicare patients with chemotherapy-induced anemia receiving erythropoiesis-stimulating agents: results from a community oncology practice. *Community Oncol*. 2009 Jun;6(6):257-261.
- Meissner B, Nelson W, Hicks R, Sikirica V, Gagne J, Schein J. The rate and costs attributable to intravenous patient-controlled analgesia errors. *Hospital Pharmacy*. 2009 Apr;44(4):312-314.
- Farias-Eisner R, Horblyuk R, Franklin M, Lunacsek O, Happe L. Economic and clinical evaluation of fondaparinux vs. enoxaparin for thromboprophylaxis following general surgery. *Curr Med Res Opin*. 2009;25(5):1081-1087.
- Happe L, Lunacsek O, Kruzikas D, Marshall G. Impact of a pentavalent combination vaccine on immunization timeliness in a state Medicaid population. *Pediatr Infect Dis J*. 2009;28(2):98-101.
- O'Day K, Salamanca-Brosig L, Regan T, Boswell K, Seal B, Reeder G. Asthma disease burden and formulary decision making: MCO and employer perspectives. *Drug Benefit Trends*. 2009;21(2):43-49.
- Reeder C, Divers C, Deem D, Cherney B, Fortner G, Probst L. Employer-based health initiative: impact on employees' cardiovascular outcomes. *Am Health Drug Benefits*. 2009 Feb/Mar;2(2):80-85.
- Jackson J, Gutierrez B, Lunacsek O, Ramachandran S. Better asthma management with advanced technology: creation of an asthma utilization Rx analyzer (AURA) tool. *P T*. 2009 Feb;34(2):80-85.
- Wall B, Chiao E, Plauschinat C, Miner P, Jackson J, Humphrey B. Trends from the field: provider organization performance assessment utilizing diabetes physician recognition program. *Am J Manag Care*. Published online February 14, 2009. <http://www.ajmc.com/publications/issue/2009/2009-02-vol15-n2/Feb09-3918p132-136>.
- Sarnes M. Impact of market trends on drug pipelines: the need for value-based R&D. *Am Health Drug Benefits*. 2009 Jan;2(1)Suppl:S55-S60.
- Dickson M, Bramley TJ, Kozma C, Doshi D, Rupnow MF. Potential drug-drug interactions with antiepileptic drugs in Medicaid recipients. *Am J Health Syst Pharm*. 2008 Sep 15;65(18):1720-1726.
- Hines JL, Danciu SC, Shah M, Borg MJ, Biga C. Use of multidetector computed tomography after mildly abnormal myocardial perfusion stress testing in a large single-specialty cardiology practice. *J Cardiovasc Computed Tomography*. 2008 Oct 10;2(6):372-378.
- Dickson M, Bramley TJ, Kozma C, Doshi D, Rupnow MF. Potential drug-drug interactions with antiepileptic drugs in Medicaid recipients. *Am J Health Syst Pharm*. 2008 Sep 15;65(18):1720-1726.
- Bramley T, Peeples P, Walt JG, Juhasz M, Hansen JE. Impact of vision loss on costs and outcomes in Medicare beneficiaries with glaucoma. *Arch Ophthalmol*. 2008 Jun;126(6):849-856.

Goodman MJ, Jhaveri M, Saverno K, Meyer K, Nightengale B. Cost-effectiveness of second-generation antihistamines and montelukast in relieving allergic rhinitis nasal symptoms. *Am Health Drug Benefits*. 2008;1(8):26-34.

Jackson J, Sobolski J, Krienke R, Wong K, Frech-Tamas F, Nightengale B. Blood pressure control and pharmacotherapy patterns in the United States before and after the release of the Joint National Committee on the prevention, detection, evaluation, and treatment of high blood pressure (JNC 7 Guidelines). *J Am Board Fam Med*. 2008;2(1):512-521.

Sheehan D, Keene M, Eaddy M, Krulewicz S, Kraus JE, Carpenter D. Differences in medication adherence and healthcare resource utilization patterns; older versus newer antidepressant agents in patients with depression and/or anxiety disorders. *CNS Drugs*. 2008;22(11):963-973.

Comp P, Happe LE, Sarnes MW, Farrelly E. Clinically detected venous thromboembolism following hip fracture surgery with prophylaxis in a clinical practice setting. *Am J Orthop*. 2008;37(9):470-475.

Eaddy M, Shah M, Lunacsek O, Stanford R. The burden of illness of hypertension and comorbid diabetes. *Curr Med Res Opin*. 2008;24(9):2501-2507.

Stanford E, Chen A, Wan G, Lunacsek O, Sand P. Treatment modalities, health care resource utilization, and costs in patients diagnosed with interstitial cystitis. *Am J Obstet Gynecol*. 2008;199(1):71.e1-10.

Kwong LM, Happe LE, Horblyuk R, Farrelly E. Decreased venous thromboembolism with injectable vs oral anticoagulation after discharge for major orthopedic surgery. *J Arthroplasty*. 2008;23(6 Suppl 1):25-30.

Nutescu EA, Shorr AF, Farrelly E, Horblyuk R, Happe LE, Franklin M. Burden of deep vein thrombosis in the outpatient setting following major orthopedic surgery. *Ann Pharmacother*. 2008;42(9):1216-1221.

Shorr AF, Nutescu EA, Farrelly E, Horblyuk R, Happe LE, Franklin M. Postdischarge oral versus injectable anticoagulation following major orthopedic surgery. *Ann Pharmacother*. 2008;42(9):1222-1228.

Naslund M, Eaddy M, Kruep E, Hogue S. Cost comparison of finasteride and dutasteride for enlarged prostate in a managed care setting among Medicare-aged men. *Am J Manag Care*. 2008;14(5):S167-S172.

Issa M, Lin P, Eaddy M, Shah M, Davis EA. Comparative analysis of alpha-blocker utilization in combination with 5-alpha reductase inhibitors for enlarged prostate in a managed care setting among Medicare-aged men. *Am J Manag Care*. 2008;14(5):S160-S166.

Fenter T, Davis EA, Shah M, Lin P. Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged 65 years. *Am J Manag Care*. 2008;14(5):S154-S159.

Naslund M, Regan T, Ong C, Hogue S. 5-alpha reductase inhibitors in men with an enlarged prostate: an evaluation of outcomes and therapeutic alternatives. *Am J Manag Care*. 2008;14(5):S148-S153.

Shabsigh R, Shah M, Sand M. Erectile dysfunction and men's health: developing a comorbidity risk calculator. *J Sex Med*. 2008;5:1237-1243.

D'Souza A, Smith M, Miller L, Doyle J, Ariely R. Persistence, adherence and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. *J Manag Care Pharm*. 2008;14(3):291-301.

Reeder C, Franklin M, Bramley T. Managed care and the impact of glaucoma. *Am J Manag Care*. 2008;14:S5-S10.

Levin L, Peeples P. History of neuroprotection and rationale as a therapy for glaucoma. *Am J Manag Care*. 2008;14:S11-S14.

Varma R, Peeples P, Walt J, Bramley T. Disease progression and the need for neuroprotection in glaucoma management. *Am J Manag Care*. 2008;14:S15-S19.

McKinnon S, Goldberg L, Peeples P, Walt J, Bramley T. Current management of glaucoma and the need for complete therapy. *Am J Manag Care*. 2008;14:S20-S27.

Fang E, Law S, Walt J, Chiang T, Williams E. The prevalence of glaucomatous risk factors in patients from a managed care setting: a pilot evaluation. *Am J Manag Care*. 2008;14:S28-S36.

Hicks RW, Sikirica V, Nelson W, Schein JR, Cousins DD. Medication errors involving patient-controlled analgesia. *Am J Health-Syst Pharm*. 2008;65(5):429-440.

2002–2007

[Return to Publications](#)

St Louis EK, Gidal BE, Henry TR, Kaydanova Y, Krumholz A, McCabe PH, Montouris GD, Rosenfeld WE, Smith BJ, Stern JM, Waterhouse EJ, Schulz RM, Garnett WR, Bramley T. Conversions between monotherapies in epilepsy: expert consensus. *Epilepsy Behav*. 2007 Sep;11(2):222-234.

Poston S, Dickson M, Johnsrud M, Rupnow MF, Gdovin JM, Bramley TJ, Armstrong RB. Topiramate prescribing patterns among Medicaid patients: diagnosis, comorbidities, and dosing. *Clin Ther*. 2007 Mar;29(3):504-518.

Shorr AF, Sarnes MW, Peeples PJ, Stanford RH, Happe LE, Farrelly E. Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery. *Am J Health-Syst Pharm*. 2007 Nov;64:2349-2355.

Hensle T, Grogg A, Hyun Grace, Eaddy M, Elder J, Shah M, Batiste L, Koyle M, Caldamone A. Challenges surrounding vesicoureteral reflux: fuel for a paradigm shift in treatment. *Curr Med Res Opin*. 2007;23(4):S1-21.

Bramley T, Franklin M, Mitrzyk B. Management and treatment of insomnia and its impact on today's managed care. *Am J Manag Care*. 2007;13(5):S110-S111.

Reeder C, Franklin M, Bramley T. Current landscape of insomnia in managed care. *Am J Manag Care*. 2007;13(5):S112-S116.

Roth T, Franklin M, Bramley T. The state of insomnia and emerging trends. *Am J Manag Care*. 2007;13(5):S117-S120.

Navarro R, Mitrzyk B, Bramley T. Chronic insomnia treatment and Medicare Part D: implications for managed care organizations. *Am J Manag Care*. 2007;13(5):S121-S124.

Richardson G, Mitrzyk B, Bramley T. Circadian rhythmicity and the pharmacologic management of insomnia. *Am J Manag Care*. 2007;13(5):S125-S128.

Green M R, Dowlati A, Yellamraju L, Daniels L, Willey J, Andrews M, Leff R. Irinotecan-cisplatin therapy for patients with extensive-stage small cell lung cancer: use patterns among American medical oncologists 2000–2006. *J Thoracic Oncol*. 2007 Oct;2(10):953-956.

Happe L, Lunacsek O, Marshall G, Lewis T, Spencer S. Combination vaccine use and vaccination quality in a managed care population. *Am J Manag Care*. 2007;13:506-512.

- Marshall G, Happe L, Lunacsek O, Szymanski MD, Woods CR, Zahn M, Russell A. Use of combination vaccines is associated with improved coverage rates. *Pediatr Infect Dis J*. 2007;26:496-500.
- Black L, Runken MC, Eaddy M, Shah M. Chronic disease prevalence and burden in elderly men: an analysis of Medicare medical claims data. *J Health Care Finance*. 2007 Summer;33(4):68-78.
- Shabsigh R, Duval S, Shah M, Regan T, Juhasz M, Veltry L. Efficacy of vardenafil for the treatment of erectile dysfunction in men with hypertension: meta-analysis of clinical trial data. *Curr Med Res Opin*. 2007;23(10):2453-2460.
- Hymes J, Bickimer T, Jackson J, Bookhart B, Mody S, Piech C. Dosing patterns, drug costs and hematologic outcomes in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa. *Curr Med Res Opin*. 2007;23(8):1931-1937.
- Vargo JJ, Bramley T, Meyer K, Nightengale B. Practice efficiency and economics: the case for rapid recovery sedation agents for colonoscopy in a screening population. *J Clin Gastroenterol*. 2007;41(6):591-598.
- Evans C, Schein J, Nelson W, Crespi S, Gargiulo K, Horowicz-Mehler N, Panchal S. Improving patient and nurse outcomes: a task and time associated with two patient-controlled analgesia modalities using Delphi panels. *Pain Manag Nurs*. 2007;8(2):86-95.
- St Louis EK, Gidal BE, Henry TR, Kaydanova Y, Krumholz A, McCabe PH, Montouris GD, Rosenfeld WE, Smith BJ, Stern JM, Waterhouse EJ, Schulz RM, Garnett WR, Bramley T. Conversions between monotherapies in epilepsy: expert consensus. *Epilepsy Behav*. 2007;11(2):222-234.
- Shorr AF, Kwong LM, Sarnes M, Happe L, Farrelly E, Mody-Patel N. Venous thromboembolism after orthopedic surgery: implications of the choice for prophylaxis. *Thromb Res*. 2007;121(1):17-24.
- Posten S, Dickson M, Johnsrud M, Rupnow M, Gdovin J, Bramley T, Armstrong R. Topiramate prescribing patterns among Medicaid patients: diagnosis, comorbidities, and dosing. *Clin Ther*. 2007 Mar;29(3):504-518.
- Harding G, Vallow S, Leidy N, et al. Ease of care with patient controlled analgesia system: questionnaire development and validation. *J Adv Nurs*. 2007;59(5):530-541.
- Issa M, Regan T. Medical therapy for benign prostatic hyperplasia—present and future impact. *Am J Manag Care*. 2007;13(1 Suppl):S4-S9.
- Issa M, Runken C, Grogg A, Shah M. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride. *Am J Manag Care*. 2007;13(1 Suppl):S10-S16.
- Naslund M, Black L, Eaddy M, Batiste L. Differences in alpha blocker usage among enlarged prostate patients receiving combination therapy with 5ARIs. *Am J Manag Care*. 2007;13(1 Suppl):S17-S22.
- Fenter T, Runken C, Black L, Eaddy M. Finasteride versus dutasteride: a real-world economic evaluation. *Am J Manag Care*. 2007;13(1 Suppl):S23-S27.
- Goldstein J, Matuszweski K, Delaney C, Senagore A, Chiao E, Shah M, Meyer K, Bramley T. Inpatient economic burden of postoperative ileus associated with abdominal surgery in the United States. *P T*. 2007;32(2):82-90.
- Raebel MA, McClure DL, Chan KA, Simon SR, Feldstein AC, Lafata JE, Andrade SE, Gunter MJ, Nelson WW, Roblin D, Platt R. Laboratory evaluation of potassium and creatinine among ambulatory patients prescribed spironolactone: are we monitoring for hyperkalemia? *Ann Pharmacother*. 2007;41:193-200.

- Shah M, Butler M, Bramley T, Curtice T, Fine S. Comparison of health care costs and co-morbidities between men diagnosed with benign prostatic hyperplasia and cardiovascular disease (CVD) and men with CVD alone in a US commercial population. *Curr Med Res Opin.* 2007;23(2):417-426.
- Rolnick SJ, Jackson J, Nelson WW, Butani A, Herrinton LJ, Hornbrook M, Neslund-Dudas C, Bachman DJ, Coughlin SS. Pain management in the last six months of life among women who died of ovarian cancer. *J Pain Symptom Manage.* 2007;33(1):24-31.
- Happe L, Farrelly E, Stanford R, Sarnes M. Cost and occurrence of thrombocytopenia in patients receiving venous thromboembolism prophylaxis following major orthopedic surgeries. *J Thromb Thrombolysis.* Published online 2007 Nov;26:125-131.
- Jackson J, Fernandes A, Nelson W. A naturalistic comparison of amoxicillin/clavulanate extended release versus immediate release in the treatment of acute bacterial sinusitis in adults: a retrospective data analysis. *Clin Ther.* 2006;28(9):1462-1471.
- Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. *J Manag Care Pharm.* 2006;12(3):239-245.
- Cantrell CR, Eaddy MT, Shah MB, Regan TS, Sokol MC. Methods for evaluating adherence of antidepressant therapy: a real-world comparison of adherence and economic outcomes. *Med Care.* 2006;44(4):300-303.
- Gdovin JM, Moya F, Vishalpura T, Grogg A. A comparative pharmacoeconomic assessment of two surfactants for the prevention of respiratory distress syndrome. *J Pediatr Pharmacol Ther.* 2006;11(1):43-54.
- Naslund MJ, Chiao E, Black L, Eaddy MT. The hidden condition: status, challenges, and opportunities in the management of enlarged prostate for managed care. *Am J Manag Care.* 2006;12(4 Suppl):S76-S82.
- Issa MM, Fenter TC, Black L, Grogg AL, Kruep EJ. An assessment of the diagnosed prevalence of diseases in men 50 years of age or older. *Am J Manag Care.* 2006;12(4 Suppl):S83-S89.
- Fenter TC, Naslund MJ, Shah MB, Eaddy MT, Black L. The cost of treating the 10 most prevalent diseases in men 50 years of age or older. *Am J Manag Care.* 2006;12(4 Suppl):S90-S98.
- Naslund MJ, Issa MM, Grogg AL, Eaddy MT, Black L. Clinical and economic outcomes in patients treated for enlarged prostate. *Am J Manag Care.* 2006;12(4 Suppl):S111-S116.
- Meissner B, Dickson M, Shinogle J. Drug and medical cost effects of a drug formulary change with therapeutic interchange for statin drugs in a multistate managed Medicaid organization. *J Manag Care Pharm.* 2006;12(4):331-340.
- Raebel MA, McClure DL, Simon SR, Chan KA, Feldstein AC, Gunter MJ, Lafata JE, Harrold L, Nelson WW, Platt R. Frequency of serum creatinine monitoring during allopurinol therapy in ambulatory patients. *Ann Pharmacother.* 2006;40:386-391.
- Solberg LI, Enstad CJ, Boyle RG, Nelson WW. Physician-patient interaction for smoking cessation medications: a dance of mutual accommodation? *J Am Board Fam Med.* 2006;19:251-257.
- Patric K, Stickles J, Turpin R, Simmons JB, Jackson J, Bridges E, Shah M. Diabetes disease management in Medicaid managed care: a program evaluation. *Dis Manag.* 2006;9(3):144-156.

Stein M, Cantrell R, Sokol M, Eaddy MT, Shah MB. The national anxiety managed care database: a focus on antidepressant utilization, patient adherence, and resource utilization. *Psychiatr Serv*. 2006;57(5):673-680.

Raebel MA, Carroll NM, Simon SR, Andrade SE, Feldstein AC, Lafata JE, Nelson WW, Chan KA, Gunter MJ, Tolsma D, Platt R. Liver and thyroid monitoring in ambulatory patients prescribed amiodarone in 10 HMOs. *J Manag Care Pharm*. 2006;12:656-664.

Raebel MA, Carroll NM, Andrade SE, Chester EA, Lafata JE, Feldstein A, Gunter MJ, Nelson WW, Simon SR, Chan KA, Davis RL, Platt R. Monitoring of drugs with a narrow therapeutic range in ambulatory care. *Am J Manag Care*. 2006;12:268-274.

Meissner B, Harrison D, Carter J, Borrego M. Predicting the impact of Medicare Part D implementation on the pharmacy workforce. *Res Social Adm Pharm*. 2006;2(3):315-328.

Dornbusch D, Allegra C, Willey J, Andrews M, Leff R, Epstein J, Jones J, Lokey L, Green M R. How do U.S. medical oncologists learn and apply new clinical trials information from press releases in nonmedical media? A case study based on ECOG 4599. *The Oncologist*. 2006 Jan;11(1):31-38.

DeVane CL, Chiao E, Franklin M, Kruep E. Anxiety disorders in the 21st century: status, challenges, opportunities, and comorbidity with depression. *Am J Manag Care*. 2005;11(Suppl):S344-S353.

Sheehan DV, Eaddy MT, Shah MB, Mauch RP. Differences in total medical costs across the SSRIs for the treatment of depression and anxiety. *Am J Manag Care*. 2005;11(Suppl):S354-S361.

Keene M, Eaddy M, Nelson WW, Sarnes MW. Adherence to paroxetine CR compared with paroxetine IR in a Medicare-eligible population with anxiety disorders. *Am J Manag Care*. 2005;11(Suppl):S362-S369.

Panzer PE, Regan TS, Chiao E, Sarnes MW. Implications of an SSRI generic step therapy pharmacy benefit design: an economic model in anxiety disorders. *Am J Manag Care*. 2005;11(Suppl):S370-S379.

Eaddy M, Grogg A, Locklear J. Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. *Clin Ther*. 2005;27(2):263-272.

Eaddy MT, Druss BG, Sarnes MW, Regan TS, Frankum (Happe) LE. Relationship of total health care charges to SSRI utilization patterns including the length of antidepressant therapy. *J Manag Care Pharm*. 2005;11(2):145-150.

Frankum (Happe) LE, Nightengale B, Russo CL, Sarnes MW. Pharmacoeconomic analysis of sequential treatment pathways in the treatment of onychomycosis. *Manag Care Interface*. 2005;18(1):55-63.

Godley PJ, Maue SK, Farrelly EW, Frech F. The need for improved medical management of patients with concomitant hypertension and type 2 diabetes mellitus. *Am J Manag Care*. 2005;11(4):206-210.

Green M, Andrews M, Leff R, Willey J, Allegra C, Denes A, Epstein J, Jones J, Lokey L. Adjuvant therapy choices in patients with resected non-small-cell lung cancer: correlation of doctors' treatment plans and relevant phase III trial data. *J Oncol Pract*. 2005;1(2):37-42.

Hurley JS, Roberts M, Solberg LI, Gunter MJ, Nelson WW, Young L, Frost FJ. Laboratory safety monitoring of chronic medications in ambulatory care settings. *J Gen Intern Med*. 2005;20(4):331-333.

Johnsrud M, Crismon MI, Thompson A, Grogg A. An economic comparison of risperidone and olanzapine use within an integrated managed mental health program. *Adm Policy Men Health*. 2005;20:1-7.

- Kaliner M, Amin A, Gehling R, Crivera C, Chiao E, Vishalpura T, Bramley T. Impact of inhaled corticosteroid-induced oropharyngeal adverse effects on treatment patterns and costs in asthmatic patients: results from a Delphi panel. *Pharm Ther Dig*. 2005;30(10):573-601.
- Katon W, Cantrell CR, Sokol MC, Chiao E, Gdovin JM. Impact of antidepressant drug adherence on comorbid medication use and resource utilization. *Arch Intern Med*. 2005;165:2497-2503.
- Keene MS, Eaddy MT, Mauch RP, Regan TS, Shah M, Chiao E. Differences in compliance patterns across the SSRIs. *Curr Med Res Opin*. 2005;21:1651-1658.
- Kruep EJ, Basskin LE. Cost-minimization analysis of darbepoetin alfa versus epoetin alfa in the hospital setting. *Am J Health Syst Pharm*. 2005;62(24):2597-2603.
- Sheehan D, Chiao E, Eaddy M, Shah M, Sarnes M. Differences in patterns of therapy change across the SSRIs for treatment of depression and anxiety. *Drug Benefit Trends*. 2005;17:403-410.
- Simon SR, Andrade SE, Ellis JL, Nelson WW, Gurwitz JH, Lafata JE, Davis RL, Feldstein A, Raebel MA. Baseline laboratory monitoring of cardiovascular medications in elderly health maintenance organization enrollees. *J Am Geriatr Soc*. 2005;53(12):2165-2169.
- Andrade SE, Graham DJ, Staffa JA, Schech SD, Shatin D, La Grenade L, Goodman MJ, Platt R, Gurwitz JH, Chan KA. Health plan administrative databases can efficiently identify serious myopathy and rhabdomyolysis. *J Clin Epidemiol*. 2005;58(2):171-174.
- Davis RL, Kolczak M, Lewis E, Nordin J, Goodman M, Shay DK, Platt R, Black S, Shinefield H, Chen RT. Active surveillance of vaccine safety: a system to detect early signs of adverse events. *Epidemiology*. 2005;16(3):336-341.
- Jackson J, Frech F, Ronen R, Mullany L, Lennert B, Jhaveri V. Assessment of drug therapy management and the prevalence of heart failure in a managed care population with hypertension. *J Manag Care Pharm*. 2004;10(6):513-520.
- Kennedy DT, Paulson DM, Eddy TD, Patel PC, Patkar AD, Holdford DA, Genina VY, Griffin EN. A smoking-cessation program consisting of extensive counseling, pharmacotherapy, and office spirometry: results of a pilot project in a Veterans Administration medical center. *Pharmacotherapy*. 2004;24(10):1400-1407.
- Nelson WW, Sybilrud LE, Porter DR, et al. Erroneous manufacturer-assigned thromboplastin reagent ISI value. *Lab Med*. 2004;35(6):327-328.
- Maue SK, Segal R, Kimberlin CL, Lipowski EE. Predicting physician guideline compliance: an assessment of motivators and perceived barriers. *Am J Manag Care*. 2004;10(6):383-391.
- McLaughlin TP, Eaddy MT, Grudzinski AN. A claims analysis comparing citalopram with sertraline as initial pharmacotherapy for a new episode of depression: impact on depression-related treatment charges. *Clin Ther*. 2004;26(1):115-124.
- Mladi DM, Grogg AL, Irish WD, Lopez RB, Degen K, Swann A, Nimsch CT. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings. *Curr Med Res Opin*. 2004;20(12):1883-1893.
- Meissner BL, Moore WM, Shinogle JA, Reeder CE, Little JM. Non-sedating antihistamine utilization impact following an increase in prescription co-payment. *J Manag Care Pharm*. 2004;10(3):226-233.
- Sarnes MW, Frankum (Happe) LE. Pharmacoeconomic evaluation of antidepressant therapies. *Manag Care*. 2004;13(Suppl 6):34-41.

- Sheehan DV, Eaddy M, Sarnes M, Vishalpura T, Regan T. Evaluating the economic consequences of early antidepressant treatment discontinuation. *J Clin Psychopharmacol*. 2004;24:544-548.
- Solberg LI, Hurley JS, Roberts MH, Nelson WW, Frost FJ, Crain AL, Gunter MJ, Young LR. Measuring patient safety in ambulatory care: potential for identifying medical group drug-drug interaction rates using claims data. *Am J Manag Care*. 2004;10(11 Pt 1):753-759.
- Vera-Llonch M, Delea TE, Richardson E, Rupnow M, Grogg A, Oster G. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov Model. *Value Health*. 2004;7(5):569-584.
- Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. *Psychiatr Serv*. 2004;55:886-891.
- Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. *JAMA*. 2004;292(21):2585-2590.
- Saver BG, Ritzwoller DP, Maciosek M, Goodman MJ, Conrad DA, Finkelstein E, Haase M, Barrett P, Cain KC. Does payment drive procedures? Payment for specialty services and procedure rate variations in 3 HMOs. *Am J Manag Care*. 2004;10(3):229-237.
- Sapienza S, Sacco P, Floyd (Flemister) K, DiCesare J, Doan QD. Results of a pilot pharmacotherapy quality improvement program using fixed-dose, combination amlodipine/benazepril antihypertensive therapy in a long-term care setting. *Clin Ther*. 2003;25(6):1872-1887.
- Eaddy M, Bramley T, Regan T. Time to antidepressant discontinuance: a comparison of controlled-release paroxetine and immediate-release SSRIs. *Manag Care Interface*. 2003;16(12):22-27.
- Fendrick AM, Monto AS, Sarnes MW, Nightengale BS. The economic burden of non-influenza-related viral respiratory tract infection in the United States. *Arch Intern Med*. 2003;163:487-494.
- Fuller MA, Shermock KM, Secic M, Grogg AL. Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. *Pharmacotherapy*. 2003;23(8):1037-1043.
- Gianfrancesco F, Grogg AL, Mahmoud R, Wang R, Meletiche D. Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. *Clin Ther*. 2003;25(4):1150-1171.
- Godley P, Nguyen A, Yokoyama K, Rohack J, Woodward B, Chiang T. Improving hypertension care in a large group-model MCO. *Am J Health Syst Pharm*. 2003;60(6):554-564.
- Holdford D, Patkar A. Identification of the service quality dimensions of pharmaceutical education. *Am J Pharm Educ*. 2003;67(4):article 108.
- Maue SK, Jackson JH, Weiss BA, Rivo ML, Jhaveri V, Lennert B. The hypertension management program: identifying opportunities for improvement. *J Clin Hypertens*. 2003;3(Suppl 2):33-40.
- Monto AS, Bramley TJ, Sarnes M. Development of a predictive index for picornavirus infections. *Clin Infect Dis*. 2003;36:253-258.
- Offman JJ, Segal R, Russell WL, Cook DJ, Sandhu M, Maue SK, Lowenstein EH, Pourfarzib R, Blanchette E, Ellrodt G, Weingarten SR. A randomized trial of an acid-peptic disease management program in a managed care environment. *Am J Manag Care*. 2003;9(6):425-433.

Andrade SE, Majumdar SR, Chan KA, Buist DS, Go AS, Goodman M, Smith DH, Platt R, Gurwitz JH. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. *Arch Intern Med.* 2003;163(17):2052-2057.

Bramley TJ, Lerner D, Sarnes M. Productivity losses related to the common cold. *J Occup Environ Med.* 2002;44:822-829.

Gianfrancesco F, Grogg AL, Mahmoud R, Wang R, Nasrallah H. Differential effects of risperidone, olanzapine, clozapine and conventional antipsychotics on type II diabetes: findings from a large health plan database. *J Clin Psychiatry.* 2002;63:920-930.

Girts TK, Crawford AG, Goldfarb NI, Bachleda M, Grogg A. Predicting high utilization of emergency department services among patients with a diagnosis of psychosis in a Medicaid managed care organization. *Dis Manag.* 2002;5(4):189-196.

Jackson JH, Bramley TJ, Chiang TS, Jhaveri V, Frech F. Determinants of uncontrolled blood pressure in an African-American hypertensive population. *Ethn Dis.* 2002;12(4 Suppl 3):53-57.

Maue SK, Rivo ML, Weiss B, Farrelly EW, Brower-Stenger S. Effect of a primary care physician-focused, population-based approach to blood pressure control. *Fam Med.* 2002;34(7):508-513.

Offman J, Shaw M, Sadik K, Grogg A, Emery K, Lee J, Reyes E, Fullerton S. Identifying patients with gastroesophageal reflux disease—validation of a practical screening tool. *Dig Dis Sci.* 2002;47(8):1863-1869.

Mahmoud R, Kozma C, Reeder CE, Grogg AL, Meissner B. The role of pharmaceuticals in mental health care outcomes. In: *Neuropsychopharmacology—5th Generation of Progress.* Nashville, TN: American College of Neuropsychopharmacology; 2002.

Andrade SE, Gurwitz JH, Chan KA, Donahue JG, Beck A, Boles M, Buist DS, Goodman M, LaCroix AZ, Levin TR, Platt R. Validation of diagnoses of peptic ulcers and bleeding from administrative databases: a multi-health maintenance organization study. *J Clin Epidemiol.* 2002;55(3):310-313.

Donahue JG, Chan KA, Andrade SE, Beck A, Boles M, Buist DS, Carey VJ, Chandler JM, Chase GA, Ettinger B, Fishman P, Goodman M, Guess HA, Gurwitz JH, LaCroix AZ, Levin TR, Platt R. Gastric and duodenal safety of daily alendronate. *Arch Intern Med.* 2002;162(8):936-942.

Fischer LR, Defor TA, Cooper S, Scott LM, Boonstra DM, Eelkema MA, Goodman MJ. Pharmaceutical care and health care utilization in an HMO. *Eff Clin Pract.* 2002;5(2):49-57.

Putnam KG, Buist DS, Fishman P, Andrade SE, Boles M, Chase GA, Goodman MJ, Gurwitz JH, Platt R, Raebel MA, Arnold Chan K. Chronic disease score as a predictor of hospitalization. *Epidemiology.* 2002;13(3):340-346.

1998–2001

[Return to Publications](#)

Godley P, Pham H, Woodward B, Rohack J, Maue SK. Opportunities for quality improvement in hypertension care in a managed care setting. *Am J Health Syst Pharm.* 2001;58(18):1728-1733.

Mauch R, Goldstein W, Lutes M, et al. Pharmaceutical industry and payer partnerships: program overview, legal updates and panel discussion proceedings. *Manag Care.* 2001;10(9 Suppl):5-6.

Monto AS, Fendrick AM, Sarnes MW. Respiratory illness caused by picornavirus infection: a review of clinical outcomes. *Clin Ther.* 2001;23(10):1615-1627.

Ofman J, Ryu S, Borenstein J, Kania S, Lee J, Grogg A, Farup C, Weingarten S. Identifying patients with gastroesophageal reflux disease in a managed care organization. *Am J Health Syst Pharm*. 2001;58(17):1607-1613.

Phillips C, Polakoff D, Mauch RP, Maue SK. Assessment of constipation management in long-term care patients. *J Am Med Dir Assoc*. 2001;2(4):149-154.

Platt R, Davis R, Finkelstein J, Go AS, Gurwitz JH, Roblin D, Soumerai S, Ross-Degnan D, Andrade S, Goodman MJ, Martinson B, Raebel MA, Smith D, Ulcickas-Yood M, Chan KA. Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for education and research on therapeutics. *Pharmacoepidemiol Drug Saf*. 2001;10(5):373-377.

Floyd (Flemister) KM, Maue SK, Aquí W, Augello F. The prevalence and treatment patterns of constipation in the long-term care setting: a multicenter cross-sectional study. *Consultant Pharmacist*. 2000.

Nelson WW, Vermeulen LC, Geurkink EA, Ehlert DA, Reichelderfer M. Clinical and humanistic outcomes in patients with gastroesophageal reflux disease patients converted from omeprazole to lansoprazole. *Arch Intern Med*. 2000;160(16):2491-2496.

Polakoff D, Tuell KT, Collette A, Wolfe M, Floyd (Flemister) KM. Collaborative partnership for optimizing heart failure outcomes in the long-term care environment: a disease management experience. *J Am Med Dir Assoc*. 2000;1(5):217-222.

Maue SK, Segal R. Application of pharmacoeconomics and decision analysis in gastrointestinal disorders in the context of disease management. Introduction to Applied Pharmacoeconomics. Chapter 8: 144-178.

Hawkins D, Jackson J. Application of pharmacoeconomics in cardiovascular disease: economic evaluation of lipid-lowering therapies. Introduction to Applied Pharmacoeconomics. Chapter 9: 179-196.

Sarnes MW, Doan Q. Impact of drug interactions and adverse reactions on therapeutics. In: *Pharmacotherapeutics for Advanced Practice*, 1st edition. Arcangelo V, Peterson A, eds. Philadelphia, PA: Lippincott Williams and Wilkins; 2000.

Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG, Goodman MJ, Gurwitz JH, LaCroix AZ, Platt R. Inhibitors of hydroxymethylglutaryl-coenzyme a reductase and risk of fracture among older women. *Lancet*. 2000;355(9222):2185-2188.

Smalley W, Shatin D, Wysowski DK, Gurwitz J, Andrade SE, Goodman M, Chan KA, Platt R, Schech SD, Ray WA. Contraindicated use of cisapride: impact of Food and Drug Administration regulatory action. *JAMA*. 2000;284(23):3036-3039.

Lee J, Lawrence BJ, Sullivan SD, Johnson NE, Barriere SL, Lake KD, Stevenson JG. Guidelines for pharmacoeconomic research fellowships. *Pharmacotherapy*. 1999;19(9):1105-1109.

Nelson WW, Frear RS. Physician attitudes toward human growth hormone products. *Am J Health Syst Pharm*. 1999;56(1):51-56.

Willey VJ, Sarnes MW, Cziraky MJ. Counseling the patient with hyperlipidemia. *Pharm Times*. June 1999.

Meenan RT, O'Keefe-Rosetti C, Hornbrook MC, Bachman DJ, Goodman MJ, Fishman PA, Hurtado AV. The sensitivity and specificity of forecasting high-cost users of medical care. *Med Care*. 1999;37(8):815-823.

Gourley DR, Gourley GA, Solomon DK, et al. Part 1: development, implementation and evaluation of a multicenter pharmaceutical care outcomes study. *J Am Pharm Assoc*. 1998;38(5):567-573.

Solomon DK, Portner TS, Bass GE, Gourley DR, Gourley GA, Holt JM, Wicke WR, Braden RL, Eberle TN, Self TH, Lawrence BL. Part 2: Clinical and economic outcomes in the hypertension and COPD arms of a multicenter outcomes study. *J Am Pharm Assoc.* 1998;38(5):574-585.

Maine LL, Regan TS. Integrated pharmacy services: cornerstone of a new model of care at Celebration Health. *J Am Pharm Assoc.* 1998;38(2):131-136.

Nightengale BS, Crumly JM, Liao J, Lawrence BJ, Jacobs EW. Economic outcomes of antipsychotic agents in a Medicaid population: traditional agents versus risperidone. *Psychopharmacol Bull.* 1998;34:373-382.

Nightengale BS, Garrett MS, Waugh S, Lawrence BJ, Andrus J. Economic outcomes associated with the use of risperidone in a naturalistic group practice setting. *Am J Manag Care.* 1998;4:400-407.

Nightengale BS, Mauch RP. Granisetron in the treatment of chemotherapy-induced nausea and vomiting: a pharmacoeconomic review. *P T.* 1998;23:119-132.

Donahue JG, Andrade SE, Cain EM, Defor TA, Goodman MJ, Gurwitz J, Platt R. Lamotrigine and severe skin eruptions. *Pharmacoepidemiol Drug Saf.* 1998;7(6):415-417.

1991–1997

[Return to Publications](#)

Kernodle (Maue) SJ. Improving health care with clinical practice guidelines and critical pathways: implications for pharmacists in ambulatory practice. *Pharm Pract Manag Q.* 1997;17(3):76-89.

Lim D, Farup C, Lawrence BJ, et al. Gastrointestinal illness in managed care: healthcare utilization and costs. *Am J Manag Care.* 1997;3(12):1859-1872.

Splinter MY, Sagraves R, Nightengale BS, Rayburn WF. Prenatal use of medications by women giving birth at a university hospital. *South Med J.* 1997;90(5):498-502.

Viale G, Mechling L, Maislin G, Durkin M, Engelhart L, Lawrence BJ. Impact of risperidone on the use of health-care resources. *Psychiatr Serv.* 1997;48(9):1153-1159.

Abbott TA, Lawrence BJ, Wallach S. Osteoporosis: the need for comprehensive treatment guidelines. *Clin Ther.* 1996;18(1):127-149.

Mauch RP, Lawrence BJ, Nissenbaum R, Dallman J. Clinical and economic impact of fluvastatin on a managed care formulary. *Manag Care Med.* 1996;3(3):28-35.

Nightengale BS, Savage G. Oxygen transport, delivery and tuberculosis protection in the perianesthesia care unit (PACU): a cost study. *J Perianesth Nurs.* 1996;11:1-8.

Payne K, Kozma CM, Lawrence BJ. Comparing DHE and sumatriptan in the management of acute migraine: a retrospective cost-efficacy analysis. *Pharmacoeconomics.* 1996;10(1):59-71.

Roberts JS, Watrous ML, Schulz RM, Mauch RP, Nightengale BS. Quantifying the clinical significance of drug-drug interactions: scaling pharmacists' perceptions of a common interaction classification scheme. *Ann Pharmacother.* 1996;30:926-934.

Kozma CM, Motheral B, Lawrence BJ. Outcomes research and pharmacoeconomics for practicing pharmacists. Sandoz Continuing Education Series. 1995;8(1):1-15.

Nightengale BS. Cost-effectiveness of Tl-201 and Tc-99m sestamibi. *J Nucl Med Technol.* 1995;23:36-41.

Nightengale BS, Brune MB, Blizzard SP, Ashley-Johnson M, Slan S. Strontium-89 chloride for the palliative treatment of metastatic bone disease. *Am J Health Syst Pharm*. 1995;52:2189-2195.

O'chi H, Kuwayama T, Tanaka N, Hess GP, Kozma CM, Grogg AL. Japanese pharmaco-economic survey. Institute for Health Economics and Policy, Tokyo, Japan. 1995.

Grogg AL, Pittman D. Beta-blockers in congestive heart failure (CE article). *Georgia J Hospital Pharm*. 1994;8(1):8-12.

Kozma CM, Mauch RP, Reeder CE, Lawrence BJ. A literature review comparing the economic, clinical, and humanistic attributes of dihydroergotamine and sumatriptan. *Clin Ther*. 1994;16(6):137-152.

Pakulski L, Grogg AL. Steroid pretreatment for ionic contrast media. *P T*. 1994;19(6):648.

Reeder CE, Lingle EW, Schulz RM, Mauch RP Jr, Nightengale BS, Pedersen CA, Watrous ML, Zetzl SE. Economic impact of cost-containment strategies in third party programmes in the US (part I). *Pharmacoeconomics*. 1993;(2):92-103.

Hawkins D, Jackson J. Application of pharmaco-economics in cardiovascular disease: economic evaluation of lipid-lowering therapies. Introduction to Applied Pharmaco-economics. Chapter 9: 179-196.

[POSTERS](#)

[2018](#)

[2017](#)

[2014–
2016](#)

[2008–
2013](#)

[2002–
2007](#)

[1993–
2001](#)

[Return to Publications](#)

2018

[Return to Posters](#)

[Return to Publications](#)

Landsman-Blumberg P, Lokhandwala T, Le Lay A, Dean B, Stafkey-Mailey D. Standard propensity score weighting did not result in balanced cohorts, now what? Poster presented at: 34th International Conference on Pharmacoepidemiology; August 22-26, 2018; Prague, Czech Republic.

Chari A, Romanus D, Farrelly E, Huang H, Blazer M, Raju A, Noga S, Skacel T, Richardson P. Randomized clinical trial (RCT) representativeness and outcomes in relapsed/refractory multiple myeloma (RRMM) real-world patients: comparison of ASPIRE, TOURMALINE-MM1, POLLUX, and ELOQUENT-2 RCTs. Poster presented at: Society of Hematologic Oncology (SOHO) 6th Annual Meeting; September 12-15, 2018; Houston, TX.

Ruban C, Burgess SM. Atopic dermatitis: development of a literature-based conceptual model and review of patient-, observer-, and clinician-reported outcome measures. Poster presented at: International Society for Quality of Life Research 25th Annual Conference; October 24-27, 2018; Dublin, Ireland.

Senagore A, Oderd G, Morland K, Iqbal S, Kugel M, Liu S, Habib A. Prevalence and burden of opioid-induced respiratory depression and postoperative nausea/vomiting associated with the treatment of acute postoperative pain following general/colorectal surgery. Poster presented at: American Society of Colon and Rectal Surgeons; May 19-23, 2018; Nashville, TN.

Kuchenbecker U, Massanari M, Mittendorf T, Werner I. Budget impact of using FeNO in the management of asthma patients in Germany. Poster presented at: European Academy of Allergy and Clinical Immunology (EAACI) Congress; May 26-30, 2018; Munich, Germany.

Shih HC, Forys A, Le J, Kugel M, Roberto P. Medicare Part D spending trends among enrollees in employer group waiver plans compared to non-low-income subsidy enrollees. Poster presented at: Annual Research Meeting; June 24-26, 2018; Seattle, WA.

Williamson T, LaRose A, Cameron J, Lott J, Eaddy M, Hopson S, Shih HC. Rosacea treatment satisfaction surveys: matching adjusted indirect treatment comparison analysis of concerns and side effects of treatment with metronidazole gel or cream vs azelaic acid foam. Poster presented at: DERM2018 NP/PA CME Conference; July 19-22, 2018; Las Vegas, NV.

Rametta M, LaRose A, Farej R, McLeod K, Quillen A. Impact of BETACONNECT™ auto-injector on Betaseron® (interferon beta-1b) therapy adherence and patient satisfaction. Poster presented at: 2018 Annual Meeting of the Consortium of Multiple Sclerosis Centers; May 30–June 2, 2018; Nashville, TN.

Chari A, Romanus D, Farrelly E, Huang H, Blazer M, Raju A, Noga S, Skacel T, Richardson P. Randomized clinical trial (RCT) representativeness and outcomes in relapsed/refractory multiple myeloma (RRMM) real-world patients: comparison of ASPIRE, TOURMALINE-MM1, POLLUX, and ELOQUENT-2 RCTs. Poster presented at: European Hematology Association (EHA) 23rd Congress; June 14-17, 2018; Stockholm, Sweden.

Mezzio D. Assessing drug price changes over 1 year and their influence on budget impact. Poster presented at: ISPOR 23rd Annual International Meeting; May 19-23, 2018; Baltimore, MD.

Lamerato L, Harris YT, Bissoonauth AA, Patel C, Durkin M, McLeod K, Quillen A, Turner B . Characterization of patient activation, clinical assessments, and patient-reported outcomes in patients with type 2 diabetes mellitus. Poster presented at: ISPOR 23rd Annual International Meeting; May 19-23, 2018; Baltimore, MD.

Ruban C, Burgess SM. Development of a conceptual model and review of patient and observer-reported outcome measures in atopic dermatitis. Poster presented at: ISPOR 23rd Annual International Meeting; May 19-23, 2018; Baltimore, MD.

Gillard KK, Bloudek LM. Epidemiology of hyperhidrosis in the United States: a systematic literature review. Poster presented at: ISPOR 23rd Annual International Meeting; May 19-23, 2018; Baltimore, MD.

Clark RS, Gittings K, Campbell CM, Meyer KL. 2018 update of health technology assessment decisions across the globe: a focus on oncology. Poster presented at: ISPOR 23rd Annual International Meeting; May 19-23, 2018; Baltimore, MD.

Nguyen V, Kanaskar A, Migliaccio-Walle K, Shields K. Utilization and impact of value assessment frameworks on payer decisions regarding chimeric antigen receptor T-cell therapies. Poster presented at: ISPOR 23rd Annual International Meeting; May 19-23, 2018; Baltimore, MD.

Bozkaya D. Projected savings in direct and indirect costs due to reduced diabetes prevalence with vegetarian diets. Poster presented at: ISPOR 23rd Annual International Meeting; May 19-23, 2018; Baltimore, MD.

Carlton R, Regan T, Narayanan S. The economic impact of EMFLAZA® (deflazacort) for the treatment of Duchenne muscular dystrophy. Poster presented at: ISPOR 23rd Annual International Meeting; May 19-23, 2018, Baltimore, MD.

Taylor A, Wissinger E, Cadarette S, Ruiz K, Akbari M. Adverse event (AE) profile of treatments used in steroid-refractory acute graft vs host disease (SR-aGvHD) in comparison to autoimmune disease indications: a literature review. Poster presented at: Blood and Marrow Transplant Tandem Meeting; February 21-25, 2018; Salt Lake City, UT.

Parcher B, Gabriel S, Ruiz K, Ariely R, Mosnaim G. Digital technology interventions and their outcomes in moderate to severe asthmatic patients: a targeted literature review. Poster presented at: AAAAI/WAO Joint Congress; March 2-5, 2018; Orlando, FL.

Valderrama A, Duchesneau E, Zichlin M, Bhak R, Yaldo A, Appukkuttan S, Sun L, Gharibo M, Babajanyan S, Duh MS. Budget impact model of ALIQOPA® (copanlisib): introduction in relapsed follicular lymphoma treatment. Poster presented at: Academy of Managed Care Pharmacy Annual Meeting; April 23-26, 2018; Boston, MA.

Gaiser A, Abdel-Sattar M, Shamseddine N, Shields S. Payer evaluation of organizational management approaches to limit opioid abuse and overdose deaths in the United States. Poster presented at: Academy of Managed Care Pharmacy Annual Meeting; April 23-26, 2018; Boston, MA.

Mody LB, Boswell KA, Ren SP, Kaufman S, Hughes J, Sarnes EF. Payer perspective on the Academy of Managed Care Pharmacy (AMCP) Format Version 4.0 (v4.0) pre-approval dossier in a managed care network. Poster presented at: Academy of Managed Care Pharmacy Annual Meeting; April 23-26, 2018; Boston, MA.

Carlton R, Regan T, Narayanan S. The economic impact of EMFLAZA® (deflazacort) for the treatment of Duchenne muscular dystrophy. Poster presented at: Academy of Managed Care Pharmacy Annual Meeting; April 23-26, 2018; Boston, MA.

Carlton R, Regan T, Narayanan S. The economic impact of EMFLAZA® (deflazacort) for the treatment of Duchenne muscular dystrophy. Poster presented at: ISPOR 23rd Annual International Conference; May 19-23, 2018; Baltimore, MD.

Mezzio D, Brown D. Assessing drug price changes over 1 year and their influence on budget impact. Poster presented at: ISPOR 23rd Annual International Conference; May 19-23, 2018; Baltimore, MD.

Bozkaya D. Projected savings in direct and indirect costs due to reduced diabetes prevalence with vegetarian diets. Poster presented at: ISPOR 23rd Annual International Conference; May 19-23, 2018; Baltimore, MD.

Bozkaya D, Bloudek LM, O'Hara K, Kirby SL, Shah S. Rifaximin and eluxadoline utilization for irritable bowel syndrome with diarrhea (IBS-D) in the United States and budget impact analysis of switching from eluxadoline to rifaximin. Poster presented at: ISPOR 23rd Annual International Conference; May 19-23, 2018; Baltimore, MD.

Lodise TP, Law A, Spilsbury-Cantalupo M, Liao L, O'Brien G, McCart M, Eddy M. Mortality rates and predictors of in-hospital mortality among intubated and mechanically ventilated adult patients with gram-negative pneumonia. Poster presented at: 2018 American Thoracic Society International Conference; May 18-23, 2018; San Diego, CA.

Lodise TP, Law A, Spilsbury-Cantalupo M, Liao L, O'Brien G, McCart M, Eddy M. Predictors of 30-day readmission among intubated and mechanically ventilated adult patients with gram-negative pneumonia. Poster presented at: 2018 American Thoracic Society International Conference; May 18-23, 2018; San Diego, CA.

2017

[Return to Posters](#)

[Return to Publications](#)

Agashe V, Duhig A, Floyd J, Maiese B, Slaff S. Quality of life (QoL), functional status (FS), and survival in triple negative breast cancer (TNBC): discordance of definitions between a targeted literature review and stakeholder interviews. Poster presented at: ISPOR's 20th Annual European Congress; November 5-8, 2017; Glasgow, Scotland.

Campbell D, Clark R, Meyer K. Trends in oncology appraisal decisions: a comparison between the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC). Poster presented at: ISPOR's 20th Annual European Congress; November 5-8, 2017; Glasgow, Scotland.

Brown D, Bozkaya D. The economic impact of switching to Herceptin (trastuzumab) biosimilar for the treatment of metastatic breast cancer from a UK payer perspective. Poster presented at: ISPOR's 20th Annual European Congress; November 5-8, 2017; Glasgow, Scotland.

Ruban C. Assessing the healthcare cost of diabetic non-small cell lung cancer patients compared to non-small cell lung cancer patients. Poster presented at: ISPOR's 20th Annual European Congress; November 5-8, 2017; Glasgow, Scotland.

Ruban C. Assessing the utilization of diabetic non-small cell lung cancer patients compared to non-small cell lung cancer patients. Poster presented at: ISPOR's 20th Annual European Congress; November 5-8, 2017; Glasgow, Scotland.

Ruban C. Investigation of demographic differences for non-small cell lung cancer patients with and without type 2 diabetes. Poster presented at: ISPOR's 20th Annual European Congress; November 5-8, 2017; Glasgow, Scotland.

McLeod K. Remote therapy management of patients on automated peritoneal dialysis demonstrates cost savings in Germany and Italy. Poster presented at: ISPOR's 20th Annual European Congress; November 5-8, 2017; Glasgow, Scotland.

Brown D, Campbell C, Migliaccio-Walle K, Jackson J, Meyer K. Recent trends in provider perceptions and use of value frameworks in the United States (US). Poster presented at: ISPOR's 20th Annual European Congress; November 5-8, 2017; Glasgow, Scotland.

O'Day K, Campbell D, Meyer K. When the outcome of an appraisal is not nice: a review of NICE appeals. Poster presented at: ISPOR's 20th Annual European Congress; November 5-8, 2017; Glasgow, Scotland.

O'Day K, Campbell D, Meyer K. Do NICE appeals make a difference? Impact of appeals on appraisal outcomes. Poster presented at: ISPOR's 20th Annual European Congress; November 5-8, 2017; Glasgow, Scotland.

Sarnes E, Cadarette S, Gittings K, Kulp W, Ruiz K, Wissinger E. A comparison of health technology (HTA) requirements for systematic literature reviews (SLRs). Poster presented at: ISPOR's 20th Annual European Congress; November 5-8, 2017; Glasgow, Scotland.

Clark R, Campbell C, Meyer K. 2017 update of recent trends in multiple sclerosis-related health technology assessment decisions: an assessment of five countries. Poster presented at: ISPOR's 20th Annual European Congress; November 5-8, 2017; Glasgow, Scotland.

Bloudek L, O'Day K. Assessment of economic model stability by repeated one-way sensitivity analysis. Poster presented at: ISPOR's 20th Annual European Congress; November 5-8, 2017; Glasgow, Scotland.

Stafkey-Mailey D, Wang W, Murty S, Shetty S. Validation of an algorithm to identify death in administrative claims data. Poster presented at: AMCP's Nexus Meeting; October 16-19, 2017; Dallas, TX. *Gold Medal Winner*.

Wang W, Shetty S, Murty S, Stafkey-Mailey D. The direct cost of cardiovascular disease-related death in patients with type 2 diabetes mellitus in a Medicare population. Poster presented at: AMCP's Nexus Meeting; October 16-19, 2017; Dallas, TX. *Bronze Medal Winner*.

Kaufman S, Hughes J, Duhig A. The current status of outcomes-based contracting for manufacturers and payers: an AMCP membership survey. Poster presented at: AMCP's Nexus Meeting; October 16-19, 2017; Dallas, TX. *Silver Medal Winner*.

Ta J, Bonine N, Harrington A, Shih V, Stafkey-Mailey D, Fuldeore RM, Yue B, Gillard P, Banks E. Healthcare resource utilization and costs of surgery for the treatment of uterine fibroids. Poster presented at: AMCP's Nexus Meeting; October 16-19, 2017; Dallas, TX.

McLeod K, Duhig A, Ogbonnaya A, Quillen A, Yue B. Prospective study of real-world outcomes in the treatment of neurogenic orthostatic hypotension with droxidopa. Poster presented at: AMCP's Nexus Meeting; October 16-19, 2017; Dallas, TX.

Moreland K, Kugel M, Liu T. Burden of post-operative nausea or vomiting associated with acute postoperative pain treatment. Poster presented at: AMCP's Nexus Meeting; October 16-19, 2017; Dallas, TX.

Chiang T, Poplar B, Hilton P, Kaufman S, Hughes J, Jackson J, Sarnes M. Cell and gene therapy evaluation and coverage challenges. Poster presented at: AMCP's Nexus Meeting; October 16-19, 2017; Dallas, TX.

Oderda GM, Morland K, Iqbal SU, Soergel DG, Kugel M, Liu S, Habib AS, Senagore AJ. Burden of postoperative nausea or vomiting associated with acute postoperative pain treatment. Poster presented at: Academy of Managed Care Pharmacy Nexus 2017; October 16-19, 2017; Dallas, TX.

Senagore AJ, Habib AS, Morland K, Iqbal SU, Soergel DG, Kugel M, Liu S, Oderda GM. Predictors of postoperative nausea and vomiting associated with opioid-treated acute postoperative pain. Poster presented at: PAINWeek 2017; September 5-9, 2017; Las Vegas, NV.

Farsani SF, Brodovicz KG, Soleymanlou N, Marquard J, Wissinger E, Maiese BA. Incidence and prevalence of diabetic ketoacidosis in adults with type 1 diabetes: a systematic literature review. Poster presented at: the American Diabetes Association 77th Scientific Sessions Conference; June 9-13, 2017; San Diego, CA.

Germino R, Rametta M, McLeod K, McCart M, Quillen A. An interim analysis of the impact of BETACONNECT™ auto-injector on patient adherence to Betaseron® (interferon beta-1b) therapy. Poster presented at: the 2017 Annual Meeting of the Consortium of Multiple Sclerosis Centers; May 24–27, 2017; New Orleans, LA.

Clark R, Campbell CM, Meyer KL. Results, rationales, and trends in health technology assessments for novel diabetes agents. Poster presented at: ISPOR's 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

Mezzio D, Kiselica A, Nguyen V, O'Day K. Immediate discounts versus delayed rebates: a survey of US payers. Poster presented at: ISPOR's 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

Duhig A, Jackson J, Sarnes M, Kaufman S, Popelar B. The exchange of healthcare economic information in the US: payer and manufacturer experiences with FDAMA 114 and future directions. Poster presented at: ISPOR's 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

Tennant L, Gittings K, Migliaccio-Walle K, Campbell C, Danavar A. Payer perceptions and utilization of the Institute for Clinical and Economic Review (ICER) value assessment framework. Poster presented at: ISPOR's 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

Stafkey-Mailey D, Yue B. Treatment patterns among patients diagnosed with advanced melanoma in a commercially insured population. Poster presented at: ISPOR's 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

Ogbonnaya A, Hennenfent K, Eaddy M. Evaluation of treatment patterns among patients with diffuse large B-cell lymphoma (DLBCL). Poster presented at: ISPOR's 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

Farrelly E, Blazer M, Ogbonnaya A, Eaddy M. Beyond hypomethylating agents (HMAS): treatment of patients with higher-risk myelodysplastic syndromes (HR-MDS) after first-line therapy (1LT) using a United States (US) electronic medical record (EMR). Poster presented at: ISPOR's 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

Liu T, Benjamin N, Popelar B. A1C levels and factors associated with glycemic control among patients with diabetes mellitus in the US. Poster presented at: ISPOR's 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

O'Day K, Meyers K. Economic impact of treating severe hemophilia A patients with plasma-derived factor-VIII/VWF versus recombinant factor-VIII in the United States. Poster presented at: ISPOR's 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

Ogbonnaya A, Lokhandwala T, Duhig A. Does the commercial availability of clobazam affect healthcare resource utilization and costs among patients with Lennox-Gastaut syndrome? Poster presented at: ISPOR's 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

Carlton R, Eaddy M. The cost-effectiveness of albumin in the treatment of decompensated cirrhosis and ascites requiring large volume paracentesis. Poster presented at: ISPOR's 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

Parcher B, Shamseddine N, Walters T, Campbell C. US payer assessment of late-stage clinical trials involving digital health technologies and pharmaceutical manufacturers. Poster presented at: ISPOR's 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

O'Day K, Brown D. Cohort analysis methods to estimate the budget impact of oncology treatments by line of therapy. Poster presented at: ISPOR's 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

Liu T, Ruiz K, Colby J. Estimation of survival outcomes for use in oncology value frameworks. Poster presented at: ISPOR's 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

Germino R, Liao L, Blazer M, Ogbonnaya A. Treatment patterns in non-cystic fibrosis bronchiectasis (NCFB): a 2-year assessment post-exacerbation. Poster presented at: the 2017 American Thoracic Society (ATS) International Conference; May 19-24, 2017; Washington, DC.

Bell J, Galaznik A, Farrelly E, Blazer M, Ogbonnaya A, Raju A, Eaddy M, Fram RJ, Faller DV. Survival outcomes after first-line therapy in higher-risk myelodysplastic syndromes (HR-MDS) using a US electronic medical record (EMR)-based cohort. Poster presented at: the 14th International Symposium for Myelodysplastic Syndromes; May 3-6, 2017; Valencia, Spain.

Nguyen V, Mezzio D, Kiselica A, O'Day K. Relative versus absolute risk framing in healthcare decision-making: a survey of U.S. payers. Poster presented at: AMCP's Annual Meeting; March 27-30, 2017; Denver, CO. *Gold Medal Winner*.

Campbell C, Migliaccio-Walle K, O'Day K, Byars C, Jackson J. Recent trends in payer perception and use of value frameworks in the United States (US). Poster presented at: AMCP's Annual Meeting; March 27-30, 2017; Denver, CO. *Silver Medal Winner*.

Popelar B, Sarnes M, Duhig A, Kaufman S, Jackson J. FDAMA 114 for the exchange of healthcare economic information: payer experiences, attitudes, and perceptions of current legislation and future directions. Poster presented at: AMCP's Annual Meeting; March 27-30, 2017; Denver, CO. *Silver Medal Winner*.

Popelar B, Jackson J, Duhig A, Sarnes M, Kaufman S. FDAMA 114 for the exchange of healthcare economic information: manufacturer experiences, attitudes, and perceptions of current legislation and future directions. Poster presented at: AMCP's Annual Meeting; March 27-30, 2017; Denver, CO. *Bronze Medal Winner*.

O'Day K, Brown D. Cost impact of elotuzumab in second-line+ vs third-line+ relapsed refractory multiple myeloma in a commercial health plan. Poster presented at: AMCP's Annual Meeting; March 27-30, 2017; Denver, CO.

Stafkey-Mailey D, Bhor M, Lokhandwala T, Elliott B. Adherence, persistence, and dosing patterns of eltrombopag for treatment of immune thrombocytopenia. Poster presented at: AMCP's Annual Meeting; March 27-30, 2017; Denver, CO.

Yue B, Lankford M, Landsman-Blumberg P. Estimating healthcare costs for advanced metastatic bladder cancer patients who are lost to follow-up: applications of the Kaplan-Meier sampling average (KMSA). Poster presented at: The American Society of Clinical Oncology (ASCO) 2017 Quality Care Symposium; March 3-4, 2017; Orlando, FL.

Bell J, Galaznik A, Farrelly E, Blazer M, Che Shih H, Ogonnaya A, Eaddy M, Dezube B. Treatment patterns among patients with higher-risk myelodysplastic syndromes in a real-world setting: electronic medical record-based data. Poster presented at: The American Society of Clinical Oncology (ASCO) 2017 Quality Care Symposium; March 3-4, 2017; Orlando, FL.

Romanus D, Raju A, Yong C, Farrelly E, Luptakova K, Labotka R, Noga S, Blazer M, Hari P. Association between treatment regimen type in second-line therapy and duration of therapy and time to next treatment in a United States (US) relapsed/refractory multiple myeloma (RRMM) cohort. Poster presented at: The 16th International Myeloma Workshop; March 1-4, 2017; New Delhi, India.

Romanus D, Raju A, Farrelly E, Skacel T, Blazer M, Hari P. Newly diagnosed multiple myeloma (NDMM): effect of age, renal insufficiency, and cardiovascular disease on overall survival and treatment patterns among stem cell transplant-ineligible patients in the United States (US). Poster presented at: The 16th International Myeloma Workshop; March 1-4, 2017; New Delhi, India.

Romanus D, Raju A, Farrelly E, Noga S, Blazer M, Hari P. Treatment patterns and outcomes by line of therapy (LOT) in a large United States (US) cohort of transplant-ineligible patients with multiple myeloma in the era of novel agents. Poster presented at: The 16th International Myeloma Workshop; March 1-4, 2017; New Delhi, India.

Romanus D, Raju A, Farrelly E, Luptakova K, Blazer M, Hari P. Triplet therapy and overall survival in routine practice among transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM) in the United States (US). Poster presented at: The 16th International Myeloma Workshop; March 1-4, 2017; New Delhi, India.

Romanus D, Raju A, Farrelly E, Luptakova K, Blazer M, Hari P. Predictors of treatment with triplet first-line therapy among transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM) in routine clinical care. Poster presented at: The 16th International Myeloma Workshop; March 1-4, 2017; New Delhi, India.

Lankford M, Willey J, Buettner A, Britton S, Scharf M, Dreicer R. Prescribing preferences of US oncologists for patients with metastatic urothelial carcinoma at first recurrence: impact of novel agents. Poster presented at: Genitourinary Cancers Symposium; February 16-18, 2017; Orlando, FL.

2014–2016

[Return to Posters](#)

[Return to Publications](#)

Brown D, Lehnigk U, Karjalainen M, Locklear J. Patient and caregiver reported problems in the utilisation of epinephrine auto-injectors for management of severe allergic reactions. Poster presented at: 4th Food Allergy and Anaphylaxis Meeting (FAAM); October 13-15, 2016; Rome, Italy.

Brown D, Lehnigk U, Karjalainen M, Locklear J. Weaknesses of treatment guidelines for the management of anaphylaxis and healthcare utilization following an anaphylaxis event. Poster presented at: 4th Food Allergy and Anaphylaxis Meeting (FAAM); October 13-15, 2016; Rome, Italy.

Brown D, Lehnigk U, Karjalainen M, Locklear J. Retrospective database analysis on anaphylaxis and patient concordance in the United States. Poster presented at: 4th Food Allergy and Anaphylaxis Meeting (FAAM); October 13-15, 2016; Rome, Italy.

Maiese B, Cadarette S, Campbell D, Arvin-Berod C. Findings of a literature review in support of a patient count model (PCM) for hepatitis C virus (HCV) in the EU5. Poster presented at: ISPOR's 19th Annual European Congress; October 29-November 2, 2016; Vienna, Austria.

Sarnes E, Shields K, Kaufman S, Meyer K. Global value dossiers (GVDs): how to ensure the value isn't lost in translation. Poster presented at: ISPOR's 19th Annual European Congress; October 29-November 2, 2016; Vienna, Austria.

Clark R, Meyer K, Campbell C. Health technology assessment decisions for novel psoriasis and psoriatic arthritis agents: results, rationale, and trends. Poster presented at: ISPOR's 19th Annual European Congress; October 29-November 2, 2016; Vienna, Austria.

Brown D. Retrospective database analysis on anaphylaxis and patient concordance in the United States. Poster presented at: ISPOR's 19th Annual European Congress; October 29-November 2, 2016; Vienna, Austria.

Stafkey-Mailey D. Real-world treatment patterns and outcomes for patients with advanced soft tissue sarcoma receiving systemic therapy in the United Kingdom. Poster presented at: ISPOR's 19th Annual European Congress; October 29-November 2, 2016; Vienna, Austria.

O'Day K, Campbell D. Cost-utility analysis of exercise for the prevention of cancer. Poster presented at: ISPOR's 19th Annual European Congress; October 29-November 2, 2016; Vienna, Austria.

Stafkey-Mailey D. Advanced soft tissue sarcoma: systemic treatment patterns and survival in Germany. Poster presented at: ISPOR's 19th Annual European Congress; October 29-November 2, 2016; Vienna, Austria.

O'Day K, Campbell D. Results from a model to forecast the current and future number of patients eligible for treatment of refractory advanced nonsmall cell lung cancer (NSCLC) in France, Germany, Italy and Spain. Poster presented at: ISPOR's 19th Annual European Congress; October 29-November 2, 2016; Vienna, Austria.

Agashe V, O'Day K, Arvin-Berod C, Meyer K, Bramley T. Potential impact of the Cancer Drugs Fund reform on orphan cancers. Poster presented at: ISPOR's 19th Annual European Congress; October 29-November 2, 2016; Vienna, Austria.

Boswell K, Mody L, Sawchyn B, Sarnes E. Value, utility, and challenges with the Academy of Managed Care Pharmacy (AMCP) format dossier: implications of version 4.0 (v4.0). Poster presented at: AMCP Nexus 2016; October 3-6, 2016; National Harbor, MD. *Gold Medal Winner*.

Meyer K, Brown D, Sarnes E, Hughes J, O'Day K. Payer utilization of economic models in the AMCP format for formulary submissions: a web-based survey. Poster presented at: AMCP Nexus 2016; October 3-6, 2016; National Harbor, MD.

Bozkaya D, O'Day K. Budget impact analysis of ibrutinib for patients with first-line chronic lymphocytic leukemia. Poster presented at: AMCP Nexus 2016; October 3-6, 2016; National Harbor, MD.

Ogbonnaya A, Lokhandwala T, Landsman-Blumberg P, Duhig A. Healthcare resource utilization and projected long-term cost savings following clobazam initiation in patients with Lennox-Gastaut syndrome. Poster presented at: AMCP Nexus 2016; October 3-6, 2016; National Harbor, MD.

Landsman-Blumberg P, Carroll C, Murty S, Slaff S. Patterns of antibiotic treatment failure in pediatric community-acquired bacterial pneumonia in the USA. Poster presented at: AMCP Nexus 2016; October 3-6, 2016; National Harbor, MD.

Landsman-Blumberg P, Carroll C, Murty S, Slaff S. Antibiotic treatment failure in adults with community-acquired bacterial pneumonia: an analysis of a large US claims database. Poster presented at: AMCP Nexus 2016; October 3-6, 2016; National Harbor, MD.

Landsman-Blumberg P, Carroll C, Murty S, Slaff S. The relationship between macrolide-resistant *Streptococcus pneumoniae* and treatment failure in adults with community-acquired bacterial pneumonia by CDC region in the US. Poster presented at: AMCP Nexus 2016; October 3-6, 2016; National Harbor, MD.

François C, McLeod K, Duhig A, Ogonnaya A, Quillen A, Cannon J, Padilla B, Shiao CA, Biaggioni I. Characteristics of patients initiating droxidopa for the treatment of neurogenic orthostatic hypotension. Poster presented at: 20th International Congress of Parkinson's Disease and Movement Disorders; June 19-23, 2016; Berlin, Germany.

Ogonnaya A, Duhig A, Farrelly E, Che Shih H, François C, Biaggioni I, Shiao CA, Ziemann A. Impact of neurogenic orthostatic hypotension on healthcare utilization and costs associated with falls in Parkinson's disease. Poster presented at: 20th International Congress of Parkinson's Disease and Movement Disorders; June 19-23, 2016; Berlin, Germany.

Bozkaya D, Migliaccio-Walle K, O'Day K. Assessing prescription drug value in the United States: a hypothetical example comparing ASCO and ICER framework outcomes. Poster presented at: ISPOR's 21st Annual Meeting; May 21-25, 2016; Washington, DC.

Clark R, Campbell C, Meyer K, Bramley T. 2015 update of health technology assessment decisions across the globe: a focus on oncology. Poster presented at: ISPOR's 21st Annual Meeting; May 21-25, 2016; Washington, DC. *ISPOR Award Finalist*.

Coutinho A, Blumberg P, Eaddy M. Use of joinpoint regression to define phases of care in patients with advanced melanoma: an evaluation from metastatic diagnosis until death. Poster presented at: ISPOR's 21st Annual Meeting; May 21-25, 2016; Washington, DC.

Liu T, Jackson J, Khalaf K, Meyer K, Brown D. Price elasticity of demand for new oral anticoagulant agents among patients with non-valvular atrial fibrillation. Poster presented at: ISPOR's 21st Annual Meeting; May 21-25, 2016; Washington, DC.

O'Day K, Campbell D. What's the matter with average cost-effectiveness ratios? A simple graphical explanation. Poster presented at: ISPOR's 21st Annual Meeting; May 21-25, 2016; Washington, DC.

Brown D, Saathoff F, Lehnigk U, Karjalainen M, Locklear JC. Weaknesses of treatment guidelines for the management of anaphylaxis and health care utilization following an anaphylaxis event. Poster presented at: ISPOR's 21st Annual Meeting; May 21-25, 2016; Washington, DC.

Eaddy M, Cross N, Hanna D. Predictors of low patient activation when initiating C1 esterase inhibitor therapy for hereditary angioedema. Poster presented at: ISPOR's 21st Annual Meeting; May 21-25, 2016; Washington, DC.

Eaddy M, Cross N, Hanna D. Patient comfortability in administering C1 esterase inhibitor therapy for hereditary angioedema: an evaluation of patient activation and adherence. Poster presented at: ISPOR's 21st Annual Meeting; May 21-25, 2016; Washington, DC.

Ogonnaya A, Eaddy M. Treatment patterns with topical rosacea treatment. Poster presented at: ISPOR's 21st Annual Meeting; May 21-25, 2016; Washington, DC.

Williamson T, Carlton R, Khalaf K, Lennert B, Cameron J. Cost and budget impact of topical treatments for the inflammatory papules and pustules of mild to moderate rosacea in the managed care setting. Poster presented at: ISPOR's 21st Annual Meeting; May 21-25, 2016; Washington, DC.

Khalaf K. Cost effectiveness of onabotulinumtoxinA versus PTNS and SNS for the treatment of overactive bladder from the US payer perspective. Poster presented at: ISPOR's 21st Annual Meeting; May 21-25, 2016; Washington, DC.

Sarnes E, Shields K. Evaluating "value" in metastatic colorectal cancer treatments: trends in the evidence. Poster presented at: ISPOR's 21st Annual Meeting; May 21-25, 2016; Washington, DC.

Abdel-Sattar M, Donne L, Rugani M, Kaufman S, McLaughlin T, Jackson J. Understanding the hepatitis C patient journey: insights from a patient panel in the United States. Poster presented at: ISPOR's 21st Annual Meeting; May 21-25, 2016; Washington, DC.

O'Day K, Meyer K, Bramley T. Defining end-of-life: is the short life expectancy criterion biased against young people and children? Poster presented at: ISPOR's 21st Annual Meeting; May 21-25, 2016; Washington, DC.

Guptill JT, Allen J, Runken MC, Eaddy M, Lunacsek O. A comparative assessment of IVIG therapy in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Poster presented at: AMCP's 28th Annual Meeting & Expo; April 19-22, 2016; San Francisco, CA.

Walters T, Parcher B, Campbell C, Shah M. Appraising the value of digital health technologies from the managed care perspective: insights for evidence assessment and reimbursement in the U.S. Poster presented at: AMCP's 28th Annual Meeting & Expo; April 19-22, 2016; San Francisco, CA. *First Interactive Digital Poster.*

Abdel-Sattar M, Corey L, Shields S, Snow J, Denno M. Drug pricing in the United States: payers evaluate strategies proposed by presidential candidates to lower drug costs. Poster presented at: AMCP's 28th Annual Meeting & Expo; April 19-22, 2016; San Francisco, CA. *Gold Medal Winner.*

Abdel-Sattar M, McCart M. Clinical pharmacy medication therapy management and patient follow-up to improve real-world adherence to novel oral anticoagulants: a single-center prospective study. Poster presented at: AMCP's 28th Annual Meeting & Expo; April 19-22, 2016; San Francisco, CA. *Silver Medal Winner.*

Friedman M, Snow J, McCart M. Plan sponsor perceptions on the influence of quality metrics on formulary coverage decisions. Poster presented at: AMCP's 28th Annual Meeting & Expo; April 19-22, 2016; San Francisco, CA. *Bronze Medal Winner.*

Ogbonnaya A, Lokhandwala T, Landsman-Blumberg P, Duhig A. Healthcare resource utilization among commercially insured clobazam-treated patients with Lennox–Gastaut syndrome. Poster presented at: AMCP's 28th Annual Meeting & Expo; April 19-22, 2016; San Francisco, CA.

Popelar B. Patterns and predictors of repository corticotropin injection therapy use in patients with sarcoidosis. Poster presented at: AMCP's 28th Annual Meeting & Expo; April 19-22, 2016; San Francisco, CA.

Campbell D, Mezzio D, Campbell C. Payer perceptions on the value of cost-per-outcome data in select disease states. Poster presented at: AMCP's 28th Annual Meeting & Expo; April 19-22, 2016; San Francisco, CA.

Popelar B. Real-world treatment patterns and demographic, clinical and economic characteristics of systemic lupus erythematosus (SLE) patients initiating repository corticotropin injection therapy. Poster presented at: AMCP's 28th Annual Meeting & Expo; April 19-22, 2016; San Francisco, CA.

Shah MV, Maiese BA, Eaddy MT, Lunacsek O, Pham A, Wan GJ. Hospitalization costs for patients undergoing orthopedic surgery treated with intravenous acetaminophen (IV-APAP) + IV opioids or IV opioids alone for postoperative pain. Poster presented at: The Annual Congress of Enhanced Recovery and Perioperative Medicine (American Society for Enhanced Recovery); April 20-22, 2016; Washington, DC.

François C, Houle C, Duhig A. Development of a neurogenic orthostatic hypotension activities of daily living (NOH ADL) scale. Poster presented at: American Academy of Neurology (AAN 2016); April 15-21, 2016; Vancouver, BC.

Ng-Mak DS, O'Day K, Chuang CC, Friedman ML, Rajagopalan K, Loebel A. Cost savings associated with improved adherence among patients with schizophrenia using lurasidone. Poster presented at: American Psychiatric Association (APA) Annual Meeting; May 14-18, 2016; Atlanta, GA.

O'Malley P, Lee A, O'Day K, Friedman M. Multiple sclerosis relapse-related costs of oral disease-modifying therapies in Denmark: an economic analysis comparing delayed-release dimethyl fumarate, fingolimod, and teriflunomide. Poster presented at: 2nd Congress of the European Academy of Neurology; May 28-31, 2016; Copenhagen, Denmark.

O'Day K, Campbell D. Cost-utility analysis of chocolate consumption for prevention of cardiometabolic disease. Poster presented at: ISPOR's 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

Jacob C, Meise D, Mittendorf T, Braun S. The use of real world evidence to support market access of medical devices—implications for the German setting. Poster presented at: ISPOR's 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

Haas J, Jacob C, Braun S. Comparative effectiveness of granulocyte colony-stimulating factors (G-CSF) for reducing incidence of febrile neutropenia (FN)-related hospitalization: a retrospective. Poster presented at: ISPOR's 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

O'Day K, Campbell D. Patient count forecasts of advanced non-small cell lung cancer: results from the UK, Germany, France, Italy and Spain (EU-5). Poster presented at: ISPOR's 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

Borchert K, Haas J, Mittendorf T, Braun S. Real world evidence in oncology—status quo in Germany. Poster presented at: ISPOR's 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

Altevers J, Borchert K, Mittendorf T, Braun S. Prevalence and incidence estimations in German AMNOG applications—the role of real-world evidence (RWE). Poster presented at: ISPOR's 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

Clark R, Meyer K, Bramley T. Trends in health technology assessment decisions across the globe: a focus on hepatitis C. Poster presented at: ISPOR's 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

Prosser C, Landsman-Blumberg P, Braun S. Treatment costs and patterns in patients with multiple sclerosis treated with prolonged-release fampridine in Germany. Poster presented at: ISPOR's 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

Lennert B, Eaddy M. The use of interquartile deviation in establishing Delphi panel consensus: a prioritization of intravenous immunoglobulin utilization. Poster presented at: ISPOR's 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

Prosser C, Altevers J, Braun S. Incidence and prevalence estimations based on claims data—new methodological considerations. Poster presented at: ISPOR's 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

McLeod K. Use of simulation to assess the impact of a remote monitoring system. Poster presented at: ISPOR's 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

O'Day K, Liu S, Bozkaya D. A method to evaluate uncertainty due to unknown parameter correlation in stochastic decision models. Poster presented at: ISPOR's 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

Kish J, Lunacsek O, Eaddy M, Willey J. The importance of duration of treatment and therapy discontinuation rates in third-line relapsed/refractory multiple myeloma patients treated in U.S. community oncology practice. Poster presented at: AMCP Nexus 2015; October 26-29, 2015; Orlando, FL.

Dandappanavar A, O'Day K. Budget impact analysis of ibrutinib for patients with previously treated chronic lymphocytic leukemia. Poster presented at: AMCP Nexus 2015; October 26-29, 2015; Orlando, FL.

Kish J, Bloudek L. Modeling the budget impact of panobinostat for the treatment of relapsed/refractory multiple myeloma from the perspective of a U.S. health plan. Poster presented at: AMCP Nexus 2015; October 26-29, 2015; Orlando, FL.

Fernandez-Lopez S, Kazzaz D, Bashir M, McLaughlin T. Assessment of pharmacists' views on biosimilar naming conventions. Poster presented at: AMCP Nexus 2015; October 26-29, 2015; Orlando, FL.

Carlton R, Campbell C, Raju A, Eaddy M. Expected costs and projected annual budget impact of treatment of varicose veins with polidocanol endovenous microfoam 1%. Poster presented at: AMCP Nexus 2015; October 26-29, 2015; Orlando, FL.

Aigbogun MS, Liu S, Kamat S, Shah M, Hartry A, Duhig A, Citrome L. Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the United States. Poster presented at: 28th Annual US Psychiatric and Mental Health Congress; September 10-13, 2015; San Diego, CA.

Morland K, Carroll C. The importance of anchor based minimal clinically important difference (MCID) to health technology assessment of established intranasal allergic rhinitis treatments. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

Popelar B, Walters T, Houle C, Duhig A. Use of work productivity endpoints in clinical studies: a review by disease state and measurement type. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

O'Day K, Campbell D. The expanded number needed to treat: applying the concept of NNT to continuous health economic outcomes. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

Knight J, Campbell D, Meyer K, Clark R. Analysis of health technology assessment in 7 Asia Oceania countries/regions: comparison of evidentiary requirements for standard and orphan drugs. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

Altevers J, Borchert K, Mittendorf T, Braun S. Use of real world evidence in German AMNOG applications. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

Clark R, Carlton R, Meyer K. Economic impact of avoidable drug wastage in patients admitted to the hospital for an acute COPD exacerbation. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

Ogbonnaya A, Kish J, Eaddy M. Rate of adverse event-related treatment changes and healthcare costs associated with topical rosacea treatment. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

Kish J, Eaddy M. Patterns of care in the workup and management of nonmetastatic and metastatic colorectal cancer. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

O'Day K, Popelar B. Budget impact analysis of enzalutamide for treatment of metastatic castration-resistant prostate cancer from a U.S. payer perspective. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

Morland K, Eaddy M. Evaluating the cost of treating bladder cancer with and without metastases. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

Kish J, Eaddy M. Cost of care for gastric cancer in patients with and without metastases. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

Carlton R, Eaddy M. Cost of treatment of radiopharmaceutical and chemotherapy for the treatment of castration-resistant prostate cancer with bone metastases in hospital setting. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

Meyer K, Clark R. The impact of endoscopic linear stapling device stability in thoracic surgery: a Delphi panel approach. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

Bozkaya D, Migliaccio-Walle K. Estimation of the budget impact of rifaximin treatment in patients with irritable bowel syndrome. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

Bozkaya D, Migliaccio-Walle K. The cost-effectiveness of disease modifying therapies for the treatment of relapsing-remitting multiple sclerosis. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

Watson C, Prosser C, Braun S, Landsman-Blumberg P, Naoshy S. Health care resource utilization before and after natalizumab initiation among multiple sclerosis patients in Germany. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

O'Day K, Flanders S, Oestreicher N, Francis P, Posta L, Popelar B, Tang H, Balk M. Budget impact analysis of enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC) from a US payer perspective. Poster presented at: American Urological Association Annual Meeting; May 15-19, 2015; New Orleans, LA.

Raju A, D'Souza A. Hypoglycemia rates and healthcare costs in patients with type 2 diabetes mellitus (T2DM) treated with 2nd line linagliptin or sulfonylurea after metformin. Poster presented at: AMCP 27th Annual Meeting & Expo; April 7-10, 2015; San Diego, CA.

Bozkaya D, Migliaccio-Walle K. The cost-effectiveness of disease modifying therapies for the treatment of relapsing-remitting multiple sclerosis. Poster presented at: AMCP 27th Annual Meeting & Expo; April 7-10, 2015; San Diego, CA.

Abdel-Sattar M, Denno M. Clinical pharmacy medication therapy management to improve real-world adherence to novel oral anticoagulants: results of a retrospective descriptive study. Poster presented at: AMCP 27th Annual Meeting & Expo; April 7-10, 2015; San Diego, CA.

Bloudek L, Eaddy M. Estimating cost per month of progression free survival (PFS) from a payer perspective: comparing commonly used treatment regimens for previously treated, i.e., relapsed and/or refractory multiple myeloma (RRMM). Poster presented at: AMCP 27th Annual Meeting & Expo; April 7-10, 2015; San Diego, CA.

Allen L, Denno M, Jackson J. Trends in medication adherence: the payer perspective. Poster presented at: AMCP 27th Annual Meeting & Expo; April 7-10, 2015; San Diego, CA.

Denno M, Klein C, Lennert B. Analyzing the burden of hepatitis C using an outcomes evaluation tool within an integrated delivery network. Poster presented at: AMCP 27th Annual Meeting & Expo; April 7-10, 2015; San Diego, CA.

Gueron B, Kish J, O'Day K, Martel MJ, Manley Daumont M. Patient count projections for advanced melanoma by line of therapy and other clinical characteristics in EU countries: results from the UK, Germany, France, Italy, and Spain (EU-5). Poster presented at: ISPOR 17th Annual European Congress; November 8-12, 2014; Amsterdam, The Netherlands.

Rouleau A, Guiraud-Diawara A, Landsman-Blumberg PB, Lokhandwala T, Stafkey-Mailey D, Verpillat P. Assessing balance in baseline characteristics using different propensity-adjusted methods for bipolar I mixed disorder patients initiating asenapine vs other oral atypical antipsychotics. Poster presented at: ISPOR 17th Annual European Congress; November 8-12, 2014; Amsterdam, The Netherlands.

Bozkaya D, Barrett AC, Migliaccio-Walle K. Cost-effectiveness of rifaximin treatment in patients with hepatic encephalopathy. Poster presented at: The Liver Meeting®, AASLD 65th Annual Meeting; November 7- 11, 2014; Boston, MA.

Lokhandwala T, Dann R, Johnson M, D'Souza AO. Costs of the diagnostic workup for lung cancer: a Medicare claims analysis. Poster presented at: The 2014 Multidisciplinary Symposium in Thoracic Oncology; October 30-November 1, 2014; Chicago, IL.

Carlton R, Campbell C, Raju A, Eaddy M. Evaluating the cost-effectiveness of interventional therapies used in the treatment of chronic venous disease. Poster presented at: AMCP Nexus 2014; October 8-9, 2014; Boston, MA. *Silver Medal Winner.*

Denno M, Klein C, Campbell C. Evaluation of outcomes in patients with overactive bladder within an integrated healthcare delivery system using a treatment patterns analyzer. Poster presented at: AMCP Nexus 2014; October 8-9, 2014; Boston, MA.

Zagadailov E, Duhig A, Denno M. The current state of patient-reported outcomes in managed care: payer perceptions of PROs and other measures of benefit. Poster presented at: AMCP Nexus 2014; October 8-9, 2014; Boston, MA. *Bronze Medal Winner.*

Knight J, Floyd J, Denno M, Allen L, Duhig A, Jackson J. Managed care perspectives on accountable care organization implementation: focus on oncology. Poster presented at: AMCP Nexus 2014; October 8-9, 2014; Boston, MA. *Bronze Medal Winner.*

O'Day K, Meyer K. Budget impact model of eslicarbazepine acetate for refractory partial-onset epilepsy in a US health insurance plan. Poster presented at: AMCP Nexus 2014; October 8-9, 2014; Boston, MA.

Bozkaya D, Migliaccio K, Bramley T. Evaluation of patient and financial outcomes associated with advanced infertility treatment options. Poster presented at: AMCP Nexus 2014; October 8-9, 2014; Boston, MA.

Chaudhari S, McLaughlin T, Morlock R, Shah MV, Cameron A, Ogale S. Extending targeted therapy beyond first-line chemotherapy backbone: real-world treatment patterns and outcomes in patients with metastatic colorectal cancer (mCRC). Poster presented at: European Society for Medical Oncology (ESMO) 16th World Congress on Gastrointestinal Cancer; June 25-28, 2014; Barcelona, Spain.

Senbetta M, Dandapanavar A, Schenkel B, O'Day K. Ibrutinib therapy for patients with relapsed or refractory chronic lymphocytic leukemia: a budget impact analysis from a US payer perspective. Poster presented at: Association for Value-Based Cancer Care 4th Annual Conference; May 6-9, 2014; Los Angeles, CA.

Faria C, Knoth R, Jackson J, Lunacsek O, Hennenfent K. The impact of anthracycline on progression-free survival and time-to-treatment failure in patients with metastatic breast cancer receiving eribulin mesylate in a community oncology setting. Poster presented at: Association for Value-Based Cancer Care 4th Annual Conference; May 6-9, 2014; Los Angeles, CA.

Faria C, Knoth R, Jackson J, Lunacsek O, Hennenfent K. Impact of the duration of prior taxanes on progression-free survival and time-to-treatment failure in patients with metastatic breast cancer receiving eribulin mesylate in a community oncology setting. Poster presented at: Association for Value-Based Cancer Care 4th Annual Conference; May 6-9, 2014; Los Angeles, CA.

Shah NP, Buettner A, Lankford M, Willey J, Neely D, Green MR. Trends in first-line tyrosine kinase inhibitor prescribing preferences among United States-based hematology-oncology physicians for patients with chronic-phase chronic myelogenous leukemia. Poster presented at: American Society of Clinical Oncology (ASCO) 50th Annual Meeting; May 30-June 3, 2014; Chicago, IL.

Green MR, Willey J, Buettner A, Lankford M, Neely DB, Ramalingam SS. Molecular testing prior to first-line therapy in patients with stage IV non-squamous non-small cell lung cancer (NSCLC): a survey of United States (US) medical oncologists (MOs). Poster presented at: American Society of Clinical Oncology (ASCO) 50th Annual Meeting; May 30-June 3, 2014; Chicago, IL.

Carlton R, Clark R. Healthcare resource utilization and rehospitalization costs of nebulized arformoterol for the treatment of chronic obstructive pulmonary disease. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting; Palais des Congrès de Montréal; May 31-June 4, 2014; Montréal, QC, Canada.

Carlton R, Zagadailov E, Bramley T. Comorbidity cost savings over 2 years of treatment with phentermine and topiramate extended-release (PHEN/TPM ER) in an overweight and obese population. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting; Palais des Congrès de Montréal; May 31-June 4, 2014; Montréal, QC, Canada.

O'Day K, Campbell C, Popelar B. Cost-utility analysis of coffee consumption for prevention of chronic disease and cancer in the United States. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting; Palais des Congrès de Montréal; May 31-June 4, 2014; Montréal, QC, Canada.

Meyer, K, O'Day K. Cost-effectiveness analysis of lurasidone vs. quetiapine XR in patients with bipolar depression. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting; Palais des Congrès de Montréal; May 31-June 4, 2014; Montréal, QC, Canada.

Zagadailov E, Carlton R, Bramley T. Budget impact of phentermine and topiramate extended-release (PHEN/TPM ER) in overweight and obese patients with comorbid prediabetes or type 2 diabetes mellitus (T2DM). Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting: Palais des Congrès de Montréal; May 31-June 4, 2014; Montréal, QC, Canada.

O'Day K, Campbell C, Popelar B, McLaughlin T. The health economic impact of coffee consumption on prevention of chronic disease and cancer in the United States. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting: Palais des Congrès de Montréal; May 31-June 4, 2014; Montréal, QC, Canada.

Campbell C, Popelar B, Dandappanavar A, Knight J, O'Day K. Cost-effectiveness analysis of coffee consumption for prevention of all-cause mortality in the United States. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting: Palais des Congrès de Montréal; May 31-June 4, 2014; Montréal, QC, Canada.

Dandappanavar A, Knight J, Campbell C, Popelar B, Jackson J, Reeder G. Factors influencing US payer coverage of elective biomarker diagnostics. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting: Palais des Congrès de Montréal; May 31-June 4, 2014; Montréal, QC, Canada.

Stafkey-Mailey D, Zagadailov E, Eaddy M. Treatment patterns and cost of care for patients with gastrointestinal stromal tumor (GIST) treated with imatinib. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting: Palais des Congrès de Montréal; May 31-June 4, 2014; Montréal, QC, Canada.

Zagadailov E, Farrelly E, Eaddy M, Stafkey-Mailey D. Evaluating costs and utilization of prostate cancer patients with bone metastases in the outpatient hospital setting. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting: Palais des Congrès de Montréal; May 31-June 4, 2014; Montréal, QC, Canada.

D'Souza AO, Morland K, Eaddy M. Treatment patterns and cost of care for patients with pancreatic cancer. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting: Palais des Congrès de Montréal; May 31-June 4, 2014; Montréal, QC, Canada.

Rodby R, Umanath K, Niecestro R, Jackson J, Dwyer J, Lewis J. Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs. Poster presented at: National Kidney Foundation Spring Clinical Meeting; April 22, 2014; Las Vegas, NV.

Lunacsek O, Bramley T. The economic burden of end-of-life care in metastatic breast cancer. Poster presented at: Academy of Managed Care Pharmacy (AMCP) 26th Annual Meeting & Expo; April 1-4, 2014; Tampa, FL.

O'Day K, Meyer K. Subcutaneous peginterferon beta-1a reduces relapse-associated costs in patients with relapsing-remitting multiple sclerosis. Poster presented at: Academy of Managed Care Pharmacy (AMCP) 26th Annual Meeting & Expo; April 1-4, 2014; Tampa, FL.

Denno M, Popelar B, Jackson J, Lennert B. Managed care perceptions and utilization of outcomes analyzers in the United States. Poster presented at: Academy of Managed Care Pharmacy (AMCP) 26th Annual Meeting & Expo; April 1-4, 2014; Tampa, FL.

Denno M, Jackson, J. Payers perspective on the future of genetic testing and personalized medicine. Poster presented at: Academy of Managed Care Pharmacy (AMCP) 26th Annual Meeting & Expo; April 1-4, 2014; Tampa, FL.

Dandappanavar A, Knight J, Campbell C, Popelar B, Jackson J, Reeder G. Payer familiarity with oncology biomarkers, their companion diagnostics, and specific plan coverage practices: results of a focus group. Poster presented at: Academy of Managed Care Pharmacy (AMCP) 26th Annual Meeting & Expo; April 1-4, 2014; Tampa, FL.

Dandappanavar A, Knight J, Campbell C, Popelar B, Jackson J, Reeder G. Factors that influence health plan decision-making in the coverage of biomarker diagnostic tests. Poster presented at: Academy of Managed Care Pharmacy (AMCP) 26th Annual Meeting & Expo; April 1-4, 2014; Tampa, FL.

Faria C, Jackson J, Lunacsek O. A comparison of time to treatment failure in metastatic breast cancer patients receiving therapy with eribulin mesylate, either with or without dosing modifications. Poster presented at: Breast Cancer Coordinated Care 2014; February 20-22, 2014; Washington, DC.

Ryan CJ, Green MR, Britton S, Buettner A, Lankford M, Neely D. Second-line prescribing preferences (PPrefs) of US-based medical oncologists (MOs) following first-line TKI use in patients with metastatic clear cell renal cell carcinoma (mccRCC). Poster presented at: 2014 Genitourinary Cancers Symposium; January 30-February 1, 2014; San Francisco, California.

Ryan CJ, Green MR, Britton S, Buettner A, Lankford M, Neely D. Prospective evaluation of prescribing preferences (PPrefs) by US-based oncologists in the post-docetaxel metastatic castration-resistant prostate cancer (mCRPC) patient. Poster presented at: 2014 Genitourinary Cancers Symposium; January 30-February 1, 2014; San Francisco, California.

Bendell JC, Lankford M, Britton S, Buettner A, Green MR, Neely D, Scharf M. Prescribing preferences (PPrefs) of US-based medical oncologists (MOs) for choice of therapy after failure of first-line FOLFOX + bevacizumab (FFB) in patients with metastatic colorectal cancer (mCRC). Poster presented at: 2014 Gastrointestinal Cancers Symposium; January 16-18, 2014; San Francisco, California.

2008–2013

[Return to Posters](#)

[Return to Publications](#)

Li Y, Suh KH, Chen W, Wei ZJ, Higuchi K. Patterns in asthma medication treatment in the US. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress; November 2-6, 2013; Dublin Ireland.

Carlton R. Cost of completing 1 year of treatment with phentermine/topiramate extended release in an overweight and obese population. Poster presented at: Obesity Society Conference; November 11-16, 2013; Atlanta, GA.

Stafkey-Mailey D, Eaddy M. Treatment patterns and costs of patients with gastrointestinal stromal tumor (GIST) receiving first-line imatinib. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting; May 18-22, 2013; New Orleans, LA.

Bramley T. Cost-effectiveness of various combinations of human papillomavirus (HPV)-based testing, including genotyping for HPV 16/18, for cervical cancer screening. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting; May 18-22, 2013; New Orleans, LA.

Carlton R, Bramley T. Cost analysis model between the cobas BRAF test and Sanger sequencing when treating malignant melanoma based on the presence of V600 mutations. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting; May 18-22, 2013; New Orleans, LA.

Denno M, Dandappanavar A, Raju A, Clark R, Campbell C, Regan T, Jackson J, Skodny P. Systematic literature review and meta-analysis of B-cell therapies in systemic lupus erythematosus. Poster presented

at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting; May 18-22, 2013; New Orleans, LA.

Bramley T. Economic considerations for mid-urethral sling procedures among patients with stress urinary incontinence. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting; May 18-22, 2013; New Orleans, LA.

Bramley T, Zagadailov E. The potential cost savings associated with preventing the development of hypertension, diabetes, and dyslipidemia in an overweight and obese population. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting; May 18-22, 2013; New Orleans, LA.

Carlton R, Clark R, Regan T. The burden of secondary cardiovascular disease in commercial and Medicare patients: a managed care perspective. Poster presented at: Academy of Managed Care Pharmacy (AMCP) 25th Annual Meeting and Expo; April 3-5, 2013; San Diego, CA.

Consaul J. Methods to detect adverse drug reactions using automated healthcare databases. Poster presented at: Academy of Managed Care Pharmacy (AMCP) 25th Annual Meeting and Expo; April 3-5, 2013; San Diego, CA.

Choti MA, Green MR, Corral M, Wong SL, Thomas M, Eaddy M. American medical oncology physician (AMOP) preferences for combined modality therapy beginning with systemic management in patients with liver-limited metastatic colorectal cancer (II-MCRC). Poster presented at: Gastrointestinal Cancers Symposium (ASCO GI); January 24-26, 2013; San Francisco, CA.

Jackson J, Chen L, Sail K, Ericson S, Haislip S, Sharpe J, Gilmore J, Saleh M. Monitoring patterns and subsequent outcomes among patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) treated with imatinib in a community setting. Poster presented at: American Society Hematology Annual Meeting and Exposition; December 7-11, 2012; Atlanta, GA.

Sail K, Chen L, Jackson J, Ericson S, Haislip S, Ibson T, Gilmore J, Saleh M. Treatment patterns among patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) treated with imatinib in a community setting. Poster presented at: American Society Hematology Annual Meeting and Exposition; December 7-11, 2012; Atlanta, GA.

Rajagopalan K, Hassan M, O'Day K, Meyer K, Grossman F. Long-term costs and outcomes of patients with schizophrenia who have previously failed an atypical antipsychotic. Poster presented at: 25th Annual U.S. Psychiatric and Mental Health Congress; November 8-11, 2012; San Diego, CA.

O'Day K, Bramley T. Sensitivity analysis versus uncertainty analysis in health economic decision making. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress; November 6, 2012; Berlin, Germany.

D'Souza A, Bramley T, Carlton R. A conjoint analysis of willingness to pay to avoid metastatic breast cancer side effects. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress; November 6, 2012; Berlin, Germany.

Bramley T, Bruno A. Patterns of treatment failure among patients receiving anticholinergics for overactive bladder (OAB) treated in a managed care setting. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress; November 6, 2012; Berlin, Germany.

Shah M, Gruschkus S, Dhamane A. Economic evaluation of reduced futile 1st line therapy in metastatic renal cell carcinoma patients using early angiogenesis-specific imaging. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress; November 6, 2012; Berlin, Germany.

McGee N. Healthy technology assessment evidence criteria: what types of evidence should be presented for products used to screen for disease in the United States? Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress; November 5, 2012; Berlin, Germany.

Meyer K. Discontinuation rates among atypical antipsychotics for schizophrenia: an indirect treatment comparison. Poster presented at: Academy of Managed Care Pharmacy's (AMCP) 2012 Educational Conference; October 4, 2012; Cincinnati, OH.

Seal B, Sullivan SD, Ramsey SD, Asche CV, Shermock K, Sarma S, Farrelly E, Eaddy M. Comparing the management and cost of hospitalized prostate cancer patients with and without bone metastases. Poster presented at: Multinational Association of Supportive Cancer Care (MASCC) International Symposium on Supportive Cancer Care; June 28-30, 2012; New York City, NY.

Sikirica V, Fridman M, Bruno A, Hodgkins P, Erder M. Factors associated with the use of psychotropic concomitant medication (PCM) for attention-deficit/hyperactivity disorder (ADHD). Poster presented at: European Network for Hyperkinetic Disorders (EUNETHYDIS) 2nd International ADHD Conference; May 23-25, 2012; Barcelona, Spain.

Bordoni R, Gilmore JW, Haislip S, et al. Factors influencing hypomethylating agent (HMA) choice in patients with myelodysplastic syndromes (MDS) seen in a community practice. Poster presented at: Second Annual Association for Value-Based Cancer Care (AVBCC) Conference; March 29-31, 2012; Houston, TX.

Seal B, Asche C, Puto K, Allen P. Patient-reported outcomes (PROs) and tolerability of therapeutic agents in patients with metastatic prostate cancer (MPC): a systematic literature review. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting; June 2-6, 2012; Washington, DC.

Rajagopalan K, O'Day K, Meyer K, Hsu J, Pikalov A. Economic impact of relapse-related hospitalization in adults with schizophrenia: results from a 12-month, double-blind lurasidone vs quetiapine XR study. Poster presented at: American Psychiatric Association 165th Annual Meeting; May 5-9, 2012; Philadelphia, PA.

Eaddy M. Comparing the management and cost of hospitalized prostate cancer patients with and without bone metastases. Poster presented at: MASCC/ISOO 2012 International Symposium on Supportive Care in Cancer; June 28-30, 2012; New York, NY.

Shah M. Outcomes after initiation of fluticasone propionate-salmeterol combination versus anti-cholinergics in patients with moderate exacerbations of COPD. Poster presented at: Academy of Managed Care Pharmacy's (AMCP) 24th Annual Meeting & Expo; April 18-20, 2012; San Francisco, CA.

Shah M. Cost-effectiveness of select first-line chemotherapy regimens in the treatment of nonsquamous non-small cell lung cancer patients in the outpatient setting. Poster presented at: Academy of Managed Care Pharmacy's (AMCP) 24th Annual Meeting & Expo; April 18-20, 2012; San Francisco, CA.

Shah M. Disease-specific costs and resource utilization associated with the initiation of insulin therapy within a type II diabetes mellitus population. Poster presented at: Academy of Managed Care Pharmacy's (AMCP) 24th Annual Meeting & Expo; April 18-20, 2012; San Francisco, CA.

Eaddy M. Evaluating the inpatient hospitalization costs of treating prostate cancer patients. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting; June 2-6, 2012; Washington, DC.

Eaddy M. Comparing the use and cost of radiopharmaceuticals in prostate cancer patients with and without bone metastasis. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting; June 2-6, 2012; Washington, DC.

Lennert B. Anticoagulants for stroke prophylaxis in a commercially insured atrial fibrillation population. Poster presented at: Academy of Managed Care Pharmacy's (AMCP) 24th Annual Meeting & Expo; April 18-20, 2012; San Francisco, CA.

Lee C, Gruschkus S, Colayco D, Bramley T, Globe D. Treatment patterns and costs of treating non-muscle-invasive bladder cancer. Poster presented at: 12th Annual meeting of the Society of Urologic Oncology in conjunction with the World Urological Oncology Federation; November 30–December 2, 2011; Rockville, MD.

Barocas D, Gallager J, Colayco D, Schwartz B, Heap K, Globe D. Utilization of immediate postoperative instillation of intravesical chemotherapy: a quality-of-care concern in older patients with non-muscle-invasive bladder cancer. Poster presented at: 12th Annual meeting of the Society of Urologic Oncology in Conjunction with the World Urological Oncology Federation; November 30–December 2, 2011; Rockville, MD.

Foran J. Treatment of higher-risk myelodysplastic syndrome (MDS) by American hematology-oncology providers (AHOPs): changes in 1st-line treatment preferences over time in relation to cytogenetics & survival data from randomized studies. Poster presented at: 2011 Annual Meeting of the American Society of Hematology; December 12, 2011; San Diego, CA.

Shah M, Chaudhari S, McLaughlin T, et al. The cost of corticosteroid-associated adverse events in systemic lupus erythematosus. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress; November 5-8, 2011; Madrid, Spain.

O'Day K, Globe D, Gruschkus SK, Peterson P. Novel methods for characterizing uncertainty in economic analysis. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress; November 5-8, 2011; Madrid, Spain.

Lalla D, McLaughlin T, Brammer M, Bramley T, Bare A, Carlton R. Willingness to pay for a reduction in risk of treatment side effects in patients with metastatic breast cancer. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress; November 5-8, 2011; Madrid, Spain.

Boswell KA, Wang J, Shah MV, Apro VS. Disease burden and treatment outcomes in second-line therapy of patients with estrogen-receptor positive (ER+) advanced breast cancer: a review of the literature. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress; November 5-8, 2011; Madrid, Spain.

Polonsky W, Rosenstock J, Gilmore A, Wei W, Chaudhari S, Riddle M. Patient reported outcomes using twice-daily insulin aspart premixed vs insulin glargine plus 1 prandial insulin glulisine or stepwise addition of glulisine to glargine in type 2 diabetes uncontrolled with oral agents. Poster presented at: American Diabetes Association 70th Scientific Sessions Abstract; June 24-28, 2011; San Diego, CA.

Kruep E, Gruschkus S, Goodwin B, Chaudhari S. Impact of length of 5 ARI therapy on clinical outcomes and costs in a population of managed care patients with benign prostatic hyperplasia. Poster presented at: American Urological Association; May 14-19, 2011; Washington, DC.

Brixner D, Eaddy M, Parkinson J. Applications in using large databases. Xcenda's short course. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual International Meeting; May 21-25, 2011; Baltimore, MD.

Lawrence C, Roy A, Harikrishnan V, Uy S, Dabbous OH. The association between self-perceived cognitive difficulties and level of depression among employees with current depression. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual International Meeting; May 21-25, 2011; Baltimore, MD.

Dexter F, Yang J, Carlton R, Bramley T, Harb G. Cost-effectiveness analysis of antiarrhythmic therapies for the treatment of supraventricular tachycardia and surgically induced tachycardias and hypertension. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual International Meeting; May 21-25, 2011; Baltimore, MD.

Ye X, Shah M, Rupnow M, Hammond J. Readmission rates and costs associated with fibrin sealant use among patients undergoing orthopedic surgery. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual International Meeting; May 21-25, 2011; Baltimore, MD.

O'Day K, McLaughlin T, Bramley T. Is it time to eliminate the ICER? Using net benefits to report the results of deterministic cost-effectiveness analyses. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual International Meeting; May 21-25, 2011; Baltimore, MD.

Barocas DA, Globe D, Colayco D, Gilmore A, Bramley T. Humanistic consequences of preventable bladder tumor recurrences in non-muscle invasive bladder cancer (NMIBC). Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual International Meeting; May 21-25, 2011; Baltimore, MD.

Lee CT, Globe D, Colayco D, Gilmore A, Bramley T. Economic consequences of preventable bladder tumor recurrences in non-muscle invasive bladder cancer. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual International Meeting; May 21-25, 2011; Baltimore, MD.

Gerson LB, Balu S, McLaughlin T, Lunacsek O, Jackson J. Examination of resource utilization patterns across subgroups of gastroesophageal reflux disease patients. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual International Meeting; May 21-25, 2011; Baltimore, MD.

Jain G, Roy A, Harikrishnan V, Yu S, Dabbous OH. Association between work productivity and severity of depression among full-time employees as measured by the WPAI & HPQ. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual International Meeting; May 21-25, 2011; Baltimore, MD.

Carlton R, Regan T, Rice G. Lower daily average consumption and greater prescription cost savings of armodafinil compared with modafinil: a 12-Month Retrospective Database Analysis. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual International Meeting; May 21-25, 2011; Baltimore, MD.

Shah M. Venous Thromboembolism prophylaxis patterns in a large oncology center. Poster presented at: MASCC/ISOO 2011 International Symposium; June 23-25, 2011; Athens, Greece.

Schwartzberg L, Jackson J, Jain G, Balu S, Buchner D. Impact of 5-HT₃ receptor antagonist selection within triple antiemetic regimens on the risk of uncontrolled chemotherapy-induced nausea and vomiting with highly emetogenic chemotherapy. Poster presented at: Hematology/Oncology Pharmacy Association 7th Annual Conference; March 23-26, 2011; Salt Lake City, UT.

Feinberg B, Gilmore J, Haislip S, Jackson J, Jain G, Balu S, Buchner D. Likelihood of a subsequent chemotherapy-induced nausea and vomiting event in patients with breast cancer receiving low

emetogenic chemotherapy. Poster presented at: Hematology/Oncology Pharmacy Association 7th Annual Conference; March 23-26, 2011; Salt Lake City, UT.

Larsen S, McLaughlin T, Allen P, Farrelly E, Sarnes M, LaFrance N. Real world use of diagnostic procedures in renal cell carcinoma. Poster presented at: Society of Nuclear Medicine (SNM) Annual Meeting; June 6, 2011; San Antonio, TX.

Yu E, Gilmore J, Gilmore AS, Lunacsek O, Yim Y, Haislip S, Feinberg S. Patient reported symptoms and treatment patterns of chemotherapy (chemo) and VEGFR/EGFR antibody therapies for the treatment of metastatic colorectal cancer in a US-community oncology setting. Poster presented at: European Society for Medical Oncology (ESMO) Congress; October 8-12, 2010; Milan, Italy.

Feinberg B, Schwartzberg LS, Gilmore J, Haislip S, Jackson J, Jain G, Balu S, Buchner D. Likelihood of a subsequent chemotherapy induced nausea and vomiting event in patients with hematologic malignancies receiving chemotherapy. Poster presented at: 52nd American Society of Hematology (ASH) Annual Meeting and Exposition; December 4-7, 2010; Orlando, FL.

Mauceri E, Jackson J, Inman M, Bramer S, Bienkowski C, Doyle JJ. Assessment of a worksite cardiometabolic intervention program: impact on hypertension awareness and control. Poster presented at: Forum 10, Disease Management Association of America (DMAA): The Care Continuum Alliance Annual Meeting; October 13-15, 2010; Washington, DC. (Won best poster)

Ejzykowicz F, Schoof-Knauer PJ, Gratz-Levenson GR, Regan T. Physician adherence to clinical guidelines for chronic heart failure and acute myocardial infarction: metropolitan vs. non-metropolitan area practices. Poster presented at: National Rural Health Association Annual Conference 2010; May 18, 2010; Savannah, GA. Slides 1-25.

Ejzykowicz F, Regan T, Gratz-Levenson G. Chronic heart failure: adherence to guidelines by physicians and adherence to therapy by patients in metropolitan vs non-metropolitan areas. Poster presented at: Academy of Managed Care Pharmacy's (AMCP) 2010 Educational Conference; October 13-15, 2010; St. Louis, MO.

Bordoni R, Feinberg BA, Gilmore JW, Haislip S, Kim E, Rege J, Jackson J, Farrelly E, Buchner D. Hematologic outcomes of MDS treatment with hypomethylating agents in community practice. Poster presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 4-8, 2010; Chicago, IL.

Wiley J, Lemke KE, Williams ME, Green MR, Lonial S. Does the magnitude of response to initial induction therapy impact plans for immediate autologous stem cell transplant (ASCT) consolidation in the transplant-eligible patient with a new diagnosis of multiple myeloma (MM)? Poster presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 4-8, 2010; Chicago, IL.

Green MR, Wozniak AJ, Wiley J, Lemke KE, West HJ. Plans of American medical oncologists (AMOs) to order molecular testing before starting first-line therapy for patients with stage IV non-small cell lung cancer (NSCLC). Poster presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 4-8, 2010; Chicago, IL.

Crawford ED, Moul JW, Pettaway C, Sutton S, Poston S, Kruep E. Using prostate-specific antigen threshold to identify increased 4-year risk of prostate cancer. Poster presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 4-8, 2010; Chicago, IL.

Brixner D, Eaddy M, Parkinson J. Real-world data methods: applications in using large retrospective databases. Xcenda's short course. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting; May 15-19, 2010; Atlanta, GA.

O'Day K, Meissner B, Bramley T. Ruling out extendedly dominated options in excel using an ICER matrix. Xcenda's Short Course. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting; May 15-19, 2010; Atlanta, GA.

O'Day K, Meissner B, Bramley T. The Cost-effectiveness sensitivity curve: quantifying the effect of individual parameter uncertainty in a probabilistic model. Xcenda's short course. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting; May 15-19, 2010; Atlanta, GA.

Eaddy M, Chen L, DuBois R, Davies EH. A comparison of intravenous and oral formulations of fludarabine in the treatment of Chronic Lymphocytic Leukemia (CLL) Xcenda's short course. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting; May 15-19, 2010; Atlanta, GA.

Shenolikar R, Burch S, Cantrell C, Gilmore A, Eaddy M. Sensitivity of medication use and outcomes to formulary controls in the elderly: a review of the literature. Xcenda's short course. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting; May 15-19, 2010; Atlanta, GA.

Rice G, Carlton R, Regan T. The Financial impact of a Daily Average Consumption (DACON) analysis in a US Pharmacy Benefit Management (PBM) company. Xcenda's short course. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting; May 15-19, 2010; Atlanta, GA.

Dhamane AD, Martin B, Brixner D, Hudson TJ, Said Q. Assessment of metabolic monitoring of patients prescribed second-generation antipsychotics (SGAs) using electronic medical record (EMR) data. Xcenda's short course. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting; May 15-19, 2010; Atlanta, GA.

Mauceri E, Bienkowski C, Hanson KA, Doyle JJ, Jackson J, Bramer S. Cardio Mission Health Poster: A health outcomes assessment of an on-site employer cardiometabolic intervention program. Poster presented at: American Occupational Health Conference (AOHC); April 26-29, 2009; San Diego, CA.

Jackson J, Kohn-Parrott KA, Parker C, Levins N, Dyer S, Hedalen EJ, Frank E, Bramer S, Brandt D, Doyle JJ. Chrysler BPSZ Study Poster: Improvements in blood pressure control and lifestyle modifications through a unique, employer-based hypertension management program (BP success zone: you auto know). Poster presented at: American Occupational Health Conference (AOHC); April 26-29, 2009; San Diego, CA.

Jackson J, Kohn-Parrott KA, Parker C, Levins N, Dyer S, Hedalen EJ, Frank E, Bramer S, Brandt D, Doyle JJ. Chrysler BPSZ Study Poster: A health outcome assessment of the introductory blood pressure success zone at Chrysler LLC. Poster presented at: American Occupational Health Conference (AOHC); April 13-16, 2008; New York, NY.

2002–2007

[Return to Posters](#)

[Return to Publications](#)

Crivera C, Varghese S, Faruqi R, Kaliner M, Bramley T, Chiao E. Reasons for non-adherence to Inhaler Corticosteroid (ICS) therapy in persistent asthma. Poster presented at: American Thoracic Society (ATS) International Conference; May 20-25, 2005; San Diego, CA.

Goldstein JL, Senagore A, Delaney C, Matuszewski K, Chiao E. The inpatient economic burden of postoperative ileus associated with abdominal surgery in the United States. Poster presented at: Digestive Disease Week (DDW); May 14-19, 2005; Chicago, IL.

Vargo J, Bramley T, Meyer K, Nightengale B. Practice efficiency for colonoscopy can be improved by utilizing a sedation agent with a recovery profile that is superior to meperidine and midazolam: results of a Monte Carlo cost simulation model. Poster presented at: Digestive Disease Week (DDW); May 14-19, 2005; Chicago, IL.

Katon WJ, Cantrell CR, Sokol MC, Gdovin JM, Chiao E. Impact of increased antidepressant adherence on comorbid medication use and economic outcomes. Poster presented at: Society of General Internal Medicine (SGIM) Annual Meeting; May 11-14, 2005; New Orleans, LA.

Kaliner M, Crivera C, Szwarcberg J, Bramley T, Chiao E. Physician responses to oropharyngeal adverse events caused by inhaled corticosteroids in adults with asthma. Poster presented at: American Academy of Allergy, Asthma & Immunology (AAAAI) 61st Annual Meeting; March 18-22, 2005; San Antonio, TX.

Gehling R, Crivera C, Szwarcberg J, Bramley T, Chiao E, Vishalpura T. Application of a Delphi technique to determine management patterns of inhaled corticosteroid-induced oropharyngeal side effects. Poster presented at: Western Society of Asthma, Allergy & Immunology (WSAAI) Annual Meeting; January 23-27, 2005; Kauai, HI.

Rosenfeld WE, Bramley TJ, Meyer K. Patient compliance with topiramate vs. other antiepileptic drugs: a claims database analysis. Poster presented at: American Epilepsy Society; December 3-8, 2004; New Orleans, LA.

Patric K, Stickles J, Bridges E, Turpin R, Jackson J. Disease management under the microscope: a demonstration and comprehensive evaluation of diabetes disease management in a Medicaid population enrolled in a network model managed care organization. Poster presented at: Disease Management Association of America (DMAA) 6th Annual Disease Management Leadership Forum (DMLF); October 20-23, 2004; Orlando, FL.

Grant D, Frieson S, Bridges E, Turpin R, Jackson J. Disease management under the microscope: a demonstration and comprehensive evaluation of a diabetes disease management program in a Medicaid program. Poster presented at: Disease Management Association of America (DMAA) 6th Annual Disease Management Leadership Forum (DMLF); October 20-23, 2004; Orlando, FL.

Frankum LE, Nightengale BS, Russo CL, Sarnes MW. Pharmacoeconomic analysis of antimycotic agents in the treatment of onychomycosis. Poster presented at: Academy of Managed Care Pharmacy (AMCP); April 2, 2004; San Francisco, CA.

Sarnes MW, Eaddy MT, Hill L, Mauch R, Regan T. The Medication Use Evaluation (MUE) software: a depression/anxiety quality improvement tool for managed care. Poster presented at: Academy of Managed Care Pharmacy (AMCP); April 2, 2004; San Francisco, CA.

Regan T, Lennert B, Eaddy M. Incorporating compliance and persistency outcomes into disease management: the national depression/anxiety managed care database study. Poster presented at: Disease Management Association of America (DMAA), Fifth Annual Disease Management Leadership Forum; October 12-15, 2003; Chicago, IL.

Bramley T, Eaddy M, Mauch R, Regan T. Treatment patterns and time to treatment discontinuation with SSRIs: comparison of a controlled-release formulation of paroxetine and immediate-release SSRIs. Poster presented at: Disease Management Association of America (DMAA), Fifth Annual Disease Management Leadership Forum; October 12-15, 2003; Chicago, IL.

Frechette A, Jackson JH, Frech F. Determinants of uncontrolled blood pressure in a hypertensive population. Poster presented at: American Academy of Nurse Practitioners (AANP) 18th Annual National Conference; June 29–July 1, 2003; Anaheim, CA.

Jackson JH, Frechette A, Farrelly E, Frech F. Modeling coronary heart disease risk reduction through improvement in blood pressure control. Poster presented at: American Academy of Nurse Practitioners (AANP) 18th Annual National Conference; June 29–July 1, 2003; Anaheim, CA.

Sheehan D, Eaddy M, Sullivan L. Evaluating the economic consequences of SSRI drop-outs in depression. Poster presented at: International Society of Pharmacoeconomics and Outcomes Research (ISPOR); May 2003; Crystal City, VA.

Jackson JH, Farrelly E, Ziska D, Lennert B, Mullany L, Frech F. Heart failure therapies within managed care. Poster presented at: American College of Clinical Pharmacy (ACCP) 2002 Annual Meeting; October 23, 2002; Albuquerque, NM.

Jackson JH, Farrelly EW, Frechette A, Lennert B, Jhaveri V, Frech F. Determinants of uncontrolled blood pressure in a hypertensive population. Poster presented at: American Heart Association (AHA) 4th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke; October 13, 2002; Washington, DC.

Jackson JH, Farrelly E, Ziska D, Lennert B, Mullany L, Frech F, Hibler S. Heart Failure therapies within managed care. Poster presented at: American Heart Association (AHA) 4th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke; October 13, 2002; Washington, DC.

Jackson JH, Farrelly E, Frechette A. Clinical and economic advantages of fixed-dose combination therapies for treatment of hypertension. Poster presented at: Academy of Managed Care Pharmacy (AMCP) 2002 Educational Conference; October 11, 2002; Washington, DC.

Grogg A, Eaddy M, Mauch R, Maue S. The effects of atypical and oral conventional antipsychotics on the compliance of mental health patients. Poster presented at: American Psychiatric Association 2002 Institute on Psychiatric Services Meeting; October 9-13, 2002; Chicago, IL.

Jackson JH, Farrelly E, Ziska D, Frech F, Hibler S. Heart failure therapies within managed care. Poster presented at: 6th Annual Scientific Meeting of the Heart Failure Society of America; September 23, 2002; Boca Raton, FL.

Maue SK, Godly P. Assessing the prescription burden of hypertensive diabetes patients within managed care plans. Poster presented at: American Diabetes Association (ADA) 62nd Annual Meeting and Scientific Sessions; June 14-18, 2002; San Francisco, CA.

Grogg A, Eaddy M, Mauch R, Maue S. The effects of antipsychotic partial compliance on resource utilization in a schizophrenia and bipolar population. Poster presented at: 42nd Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting; June 12, 2002; Boca Raton, FL.

Jackson JH, Maue SK, Godly P. Prevalence of elevated systolic blood pressure in the U.S. Poster presented at: American Heart Association's Asia Pacific Scientific Forum; April 23-26, 2002; Honolulu, HI.

Frechette A, Jackson JH, Hibler S, Godly P, Sabrsula S, Coyle-Toerner P, Weiss B. The need for improved blood pressure control within the African-American population: a multi-site assessment. Poster presented at: American College of Clinical Pharmacy (ACCP) Spring Practice and Research Forum; April 7-10, 2002; Savannah, GA.

Jackson JH, Farrelly E, Godly P. Economic impact of fixed-dose combination therapies for treatment of hypertension. Poster presented at: Academy of Managed Care Pharmacy (AMCP) 14th Annual Meeting and Showcase; April 3-6, 2002; Salt Lake City, UT.

Nightengale, BS. The disease burden and cost of illness related to VRI. Poster presented at: Symposium held during Academy of Managed Care Pharmacy (AMCP) Educational Conference: Managing the Cold War: Costs and Complications of Respiratory Illness; October 19, 2001; Dallas, TX.

Godley PJ, Nikam PT, Yokoyama KK, Maue SK, Woodward BW. Blood pressure control within the Scott and White health plan through primary care provider-focused interventions. Poster presented at: American Society of Health-Systems Pharmacists (ASHP) Mid-Year Clinical Meeting; December 3-7, 2001; New Orleans, LA.

Maue SK, Farrelly EW, Frech F. The need for improved blood pressure control within the diabetic hypertensive population. Poster presented at: The President's Poster Reception at American Diabetes Association (ADA) 61st Scientific Sessions; June 22-26, 2001; Philadelphia, PA.

Maue SK, Konerman JP, Sarnes MW. Identifying opportunities to improve clinical outcomes for high risk hypertensive patients. Poster presented at: American Society of Health-Systems Pharmacists (ASHP) Annual Meeting 2001; June 3-6, 2001; Los Angeles, CA.

Woo A, DeWolf W, Maue SK. Which standard for blood pressure control? WHO or JNC-VI? Poster presented at: American Society of Hypertension (ASH) 16th Scientific Meeting; May 15-19, 2001; San Francisco, CA.

Lennert B, Maves T, Maue SK, Jackson JH. Identifying opportunities to improve clinical outcomes in hypertension: collaboration between pharmacy and quality improvement departments at touchpoint. Poster presented at: 2001 Pharmacy Society of Wisconsin (PSW) Educational Conference; April 26-27, 2001; Madison, WI.

Maue SK, Lennert B, Godley PJ, Berney S. Assessing quality improvement in hypertension care to meet HEDIS 2000 standards. Poster presented at: 13th Annual Meeting & Showcase of the Academy of Managed Care Pharmacy (AMCP); April 18-21, 2001; Tampa, FL.

Nightengale BS, Maue SK, Farrelly EW, Frech F. Identifying hypertension patients for quality improvement: is HEDIS enough? Poster presented at: 13th Annual Meeting & Showcase of the Academy of Managed Care Pharmacy (AMCP); April 18-21, 2001; Tampa, FL.

Maue SK, Farrelly E. Quality improvement opportunities for hypertension care in a managed care setting. Poster presented at: American Society of Health-Systems Pharmacists (ASHP) Mid-Year Clinical Meeting; December 3-7, 2000; Las Vegas, NV.

Pham Hoa, Godley PJ, Rohack J, Maue SK. Quality of hypertension care among diabetics in a managed care setting: scope for improvement. Poster presented at: American Society of Health-Systems Pharmacists (ASHP) Mid-Year Clinical Meeting; December 3-7, 2000; Las Vegas, NV.

Pham HT, Godley PJ, Rohack J, Woodward B, Nightengale BS. HEDIS 2000 hypertension improvement program within a managed care organization. Poster presented at: American Society of Health-Systems Pharmacists (ASHP) Annual Meeting; June 4-7, 2000; Philadelphia, PA.

Fraser M, Mofsen R, Maue SK, Farrelly E. A quality improvement initiative for patients with behavioral disorders in the long term care environment. Poster presented at: American Geriatrics Society (AGS) Annual Meeting; May 17-21, 2000; Nashville, TN.

Maue SK, Gillis CT, Frech FH, Doan Q, Farrelly EW. Identifying opportunities to improve clinical outcomes for hypertensive patients with diabetes in a managed care setting. Poster presented at: American Society of Hypertension (ASH) 15th Scientific Meeting; May 16-20, 2000; New York, NY.

Sapienza S, Sacco P, Floyd KM, DiCesare J, Doan Q. Hypertension management in long-term care: opportunities for quality improvement. Poster presented at: American Medical Directors Association (AMDA) 2000 Annual Symposium; March 16-19, 2000; San Francisco, CA.

Fraser M, Mofsen R, Maue SK, Farrelly E. A quality improvement initiative for patients with behavioral disorders in the long term care environment. Poster presented at: University of Florida Pharmacy Health Care Administration Transatlantic Geriatrics Annual Meeting; September 1-3, 1999; Paris, France.

Fraser M, Mofsen R, Kernodle SJ. A quality improvement initiative for patients with dementia. Poster presented at: American Medical Directors Association (AMDA) Annual Meeting; March 4-7, 1999; Orlando, FL.

Rapp KL, Collette A, Mauch RP, Floyd KM. A prescription for balancing quality and cost in the changing reimbursement environment. Poster presented at: American Medical Directors Association (AMDA) Meeting; March 4-7, 1999; Orlando, FL.

Nightengale BS, Crumly JM, Kernodle SJ, Jacobs EW. Dosing trends and associated schizophrenia related health care costs from a state Medicaid perspective: risperidone versus olanzapine. Poster presented at: American Psychiatric Association (APA) Annual Meeting; January 1999.

Mauch RP, Tuell KT, Floyd KM. Assessing the impact of a heart failure health outcomes management program in a long term care environment. Poster presented at: American Society of Consultant Pharmacist (ASCP) 28th Annual Meeting and Exhibition; November 1997; Philadelphia, PA.

Description of a health outcomes management program in a long term care population. Poster presented at: American Society of Consultant Pharmacist (ASCP) 28th Annual Meeting and Exhibition; November 15, 1997; Philadelphia, PA.

Assessing the outcomes associated with implementing an H2 antagonist outcomes management program in a long term care population. Poster presented at: American Society of Consultant Pharmacist (ASCP) 28th Annual Meeting and Exhibition; November 15, 1997; Philadelphia, PA.

Mauch RM, Floyd KM. Health outcomes management program. Poster presented at: American Medical Directors Association (AMDA) Meeting; February 15, 1997; Phoenix, AZ.

Relationship of consultant type and prescription utilization in Florida long term care facilities. Poster presented at: 24th Annual Meeting and Exposition of the American Society of Consultant Pharmacists (ASCP); November 12, 1993; New Orleans, LA.